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Abstract 
A source of debate in the health care priority setting literature is whether to weight 
health gains to account for equity considerations, such as concern for those with very 
short life expectancy. This paper reviews the empirical evidence in the published social 
sciences literature relevant to the following research question: do members of the public 
wish to place greater weight on a unit of health gain for end-of-life patients than on that 
for other types of patients? An electronic search of the Social Sciences Citation Index for 
articles published until October 2017 was conducted, with follow-up of references to 
obtain additional data. Hierarchical criteria were applied to select empirical studies 
reporting stated preferences relating to hypothetical health care priority setting contexts. 
Twenty-three studies met the inclusion criteria and were included in the review. Choice 
exercises were the most common method used to elicit preferences; other approaches 
included budget allocation, person trade-off and willingness-to-pay. Some studies found 
that observed preferences regarding end-of-life patients are influenced by information 
DERXWWKHSDWLHQWV¶DJHV2YHUDOOWKHHYLGHQFHLVPL[HGZLWKeight studies that report 
evidence consistent with a µpremium¶ for end-of-life treatments and 11 studies that do 
not. Methodological and design aspects that appear to influence the findings of end-of-
life-related preference studies are identified and discussed. The findings of the UK 
studies have particular relevance for assessing the legitimacy of the National Institute for 
+HDOWKDQG&DUH([FHOOHQFH¶VSROLF\IRUDSSUDLVLQJOLIH-extending end-of-life treatments. 
 
Key words 
end of life; literature review; stated preferences; public preferences; societal 
preferences; priority setting; health economics; NICE 
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Introduction 
A source of debate in the health care priority setting literature is whether and how to 
weight health gains to account for equity considerations. Assuming it is deemed 
appropriate to apply equity weights to health gains, and irrespective of the precise way 
in which the weighting system operates, the direction and magnitude of the weights are 
matters of value judgement (Brazier et al., 2017). The importance of public participation 
in health care decision-making has been emphasised in countries such as the UK 
(Department of Health, 1997), where members of the public are both potential users and 
DVWD[SD\HUVWKHXOWLPDWHIXQGHUVRIWKHFRXQWU\¶Vhealth service. Accordingly, most 
empirical studies examining the relative value of a quality-adjusted life year (QALY) have 
involved surveys using general public samples (Brazier et al., 2017). 
Public preferences have been cited as a rationale behind the way in which life-extending 
end-of-life treatments are appraised by the National Institute for Health and Care 
Excellence (NICE). Since 2009, NICE has applied a supplementary policy which indicates 
that if certain criteria are met, it may be appropriate to recommend the use of such 
treatments even if their cost-effectiveness estimates exceed the range normally 
considered acceptable (NICE, 2009). However, there have been concerns that there is 
little evidence to support the premise that society places special value on life-extending 
end-of-life treatments (Rawlins et al., 2010). This has led to calls for evidence and 
further exploration of the issues (Green, 2011; Webb and Paterson, 2016).  
The aim of this paper is to review the published social sciences literature that is relevant 
to the following research question: do members of the public wish to place greater 
weight on a unit of health gain for end-of-life patients than on that for other types of 
patients? Policies reflecting such preferences can be described as an µend-of-life 
premium¶ (Cookson, 2013; McCabe et al., 2016). The review is in part motivated by the 
policy context in the UK, but the research question is pertinent in all countries seeking to 
understand whether there is societal support for prioritising the treatment of patients 
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with short life expectancy. It adds to the existing literature on health care priority setting 
preferences, including a recent review investigating the evidence on preferences 
regarding the weighting of health gains for cancer patients (Morrell et al., 2017).  
The review focuses on studies concerned with the prioritisation of treatment based on 
SDWLHQWV¶OLIHH[SHFWDQF\RUproximity to death), thus distinguishing it from previous 
reviews of severity of illness more generally (Shah, 2009; Nord and Johansen, 2014), 
which typically have examined studies describing severity in terms of quality-of-life.  
Methods 
SSCI search 
The primary source of data for the review was an electronic search of the Social Sciences 
Citation Index (SSCI) within the Web of Science Core Collection, first carried out in May 
2014. The search was repeated in October 2017 in order to update the review. No time 
or language limits were imposed, though the database only covers articles published 
since 1956.  
An iterative approach was used to identify search terms. The following sub-section 
therefore includes selected intermediate results, as necessary to explain the methods. 
Search terms 
Search terms were developed using an iterative process. The initial search terms were 
end-of-life and preferences (note that Web of Science automatically helps to find plurals 
and variant spellings). In order to improve the sensitivity of the search, two terms 
related to end-of-life ± severity and terminal ± were added. In a review of severity as a 
priority-setting criterion (Shah, 2009), some of the studies identified measured severity 
in terms of life expectancy. In its supplementary guidance on the appraisal of life-
extending end-of-life treatments, NICE (2009) refers to the benefits of such treatments 
being achievHG³LQWKHODWHUVWDJHVRIWHUPLQDOGLVHDVH´SDUDgraph 2.2.1).  
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$IRUPRIµZRUGIUHTXHQF\DQDO\VLV¶*ODQYLOOHet al., 2006) was then used to identify 
further search terms, in order to improve the specificity (and therefore the efficiency) of 
the search. Three articles were designated DVµNH\SDSHUV¶$EHO2OVHQ/LQOH\DQG
Hughes, 2013; Shah et al., 2014) and their abstracts were examined. These were the 
only three fully-published articles that explicitly investigated public preferences regarding 
end-of-life treatments, as defined by the NICE guidance (and therefore of direct 
relevance to the policy issue that motivated this programme of research), that were 
known to the authors at the time of developing the search strategy. Some 
discussion/working papers that addressed the topic were also known to the authors, but 
these articles were not used for the purpose of identifying search terms because they 
had not yet been published in peer-reviewed journals and their abstracts were therefore 
subject to change. 
All of the unique words that appeared in at least two of the three key paper abstracts 
were identified, and those considered to be potentially relevant to the research question 
were selected. The impact of adding these terms to the search was tested by examining 
whether their inclusion substantially reduced the number of records identified whilst 
increasing the specificity of the search. This was judged informally by assessing the 
QXPEHURIµSUREDEO\UHOHYDQW¶UHFRUGVZLWKLQWKHPRVWUHFHQWUHFRUGVAs a result of 
this process, the terms health and respondents (or its synonyms: subjects, participants, 
sample) were added. The term life expectancy was also added as a further alternative to 
end-of-life.  
Box 1 shows the final strategy (note that TS refers to topic search, covering terms in the 
titles and abstracts of articles, as well as in the keywords that have been assigned to the 
articles by the authors and Web of Science).  
<Box 1 here> 
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Selection of studies for inclusion 
To be included, articles had to meet the following hierarchical criteria: 
1. Publication: Article must be published in English and as a full text manuscript in 
a peer-reviewed journal. 
2. Empirical data: Article must review, present or analyse empirical data. 
3. Priority-setting context: Article must relate to a health care priority-setting or 
resource allocation context. Articles reporting preferences from an individual or 
µRZQKHDOWK¶perspective (rather than a social decision-maker perspective) can be 
included as long as they clearly seek to inform health care priority-setting 
policies. 
4. Stated preference data: Article must report preferences that were elicited in a 
hypothetical, stated context using a choice-based approach involving trade-offs. 
5. End-of-life: Article must inform the topic of society placing greater weight on a 
unit of health gain for end-of-life patients (i.e. patients with short life expectancy) 
than on that for other types of patients.  
6. Original research: Article must present original research and must not be solely 
a review of the literature. 
Criterion 3 was applied to ensure that the review focused on studies that can inform the 
kinds of priority-setting policy issues faced by NICE and other similar agencies. The 
exclusion of articles reporting preferences RQO\IURPDQLQGLYLGXDORUµRZQKHDOWK¶
perspective was considered, as the legitimacy of using such studies to inform decisions 
about how to allocate shared resources has been questioned (Brouwer and 
Koopmanschap, 2000). However, it was deemed appropriate not to apply this exclusion 
rule on the basis that the own health perspective studies may provide information that is 
relevant to the research question.  
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Titles and abstracts were screened for eligibility against criteria 1 to 4, sequentially. The 
full texts of potentially eligible articles were then screened against criteria 1 to 6, 
sequentially. Full texts were also screened in cases where it was not clear from the title 
and abstract which of the criteria had and had not been met.  
Whitty et al. (2014) and Gu et al. (2015) both note that there is currently no single 
standardised method for assessing the quality of stated preference studies covering the 
full range of preference elicitation techniques (though best practice guidelines do exist 
for specific methods ± e.g. Bridges et al., 2011). Hence, a formal assessment of study 
quality was not undertaken. 
Identification of additional material 
Additional material was identified by following up the reference lists of the articles whose 
full texts were screened. The same criteria were applied to these newly identified 
articles. 
Data extraction 
Data were extracted and compiled in an Excel database by author KKS. Following Whitty 
et al. (2014), it was deemed inappropriate to synthesise the preference data due to the 
variation in methods and contexts between studies, so a largely descriptive reporting 
approach was used. 
Results 
Literature search output 
The final (October 2017) SSCI search yielded 899 unique results (Figure 1). By 
comparison, the May 2014 search yielded 598 unique results. Following the review of 
titles and abstracts (in which inclusion criteria 1 to 4 were applied sequentially), 817 of 
these were excluded, mostly for failing to meet criterion 3. Commonly excluded articles 
DWWKLVVWDJHLQFOXGHGVWXGLHVDERXWDGYDQFHGLUHFWLYHVOLYLQJZLOOVVWXGLHVRISHRSOH¶V
8 
 
preferences for their own death and/or palliative care; studies focusing on the individual-
level, bedside decision-making context; and health state valuation studies. Two of the 
articles excluded for failing to meet criterion 1 were published in German; the third was 
a conference abstract with no associated full text article. 
Following a review of the full texts of the remaining 82 records (in which inclusion 
criteria 1 to 6 were applied sequentially), a further 67 were excluded. Commonly 
excluded articles at this stage reported public preferences regarding the prioritisation of 
health care resources based on severity (amongst other criteria) but did not define 
severity in terms of life expectancy, or did not report the results in such a way that 
preferences regarding life expectancy could be inferred. 
<Figure 1 here> 
The reference lists of the articles whose full texts were reviewed identified a further eight 
articles that were relevant to the research question but had not been picked up by the 
SSCI search, all of which met the criteria for inclusion. For example, two of these articles 
did not include the term health in their titles, abstracts or keywords. The additional 
articles met all six of the criteria for inclusion.  
In cases where an article described a large study comprising multiple sub-studies with 
distinct methods and/or samples (e.g. Baker et al., 2010), only the data for the sub-
studies that were relevant to the research question were extracted. 
Description of included studies 
The included articles (Table 1) were published between 2000 and 2017, with the 
majority conducted and published after NICE issued its supplementary advice on end-of-
life in January 2009. Ten of the studies (43.5%) used a solely UK-based sample, with 
the other studies originating elsewhere in Europe and in Australia, Canada, Japan, South 
Korea and the United States. Two studies included multi-country samples (Pennington et 
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al., 2015; Shiroiwa et al., 2010). The distribution of key variables across the 23 articles 
is shown in Table 2. Full details are available in the supplementary appendix. 
<Table 1 here> 
<Table 2 here>
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Methods used to elicit preferences 
The majority of studies elicited preferences using some form of choice exercise whereby 
respondents were presented with multiple hypothetical patients (or patient groups) and 
were asked which they thought should be treated. In most cases the tasks involved 
pairwise choices, though Dolan and Shaw (2004) and Dolan and Tsuchiya (2005) both 
asked respondents to choose between six alternatives. Five of the choice exercise 
studies explicitly applied the DCE method as defined by Carson and Louviere (2011) ± 
that is, an approach in which choices are made between discrete alternatives where at 
least one attribute is systematically varied in such a way that information related to 
preference parameters of an indirect utility function can be inferred. 
A related approach, budget allocation, used in two studies (Linley and Hughes, 2013; 
Chim et al., 2017), allows respondents to indicate the strength of their preference by 
specifying how funding should distributed among the candidate beneficiaries. The results 
of this method can be simplified by reporting, for example, whether respondents gave 
the majority of the budget to one group or another, or opted for an equal allocation 
between the groups.  
Most of the studies used methods that are well-established in the field of health care 
preference elicitation (Ryan et al., 2001). A more novel approach, which combined 
elements of the budget allocation and choice exercise techniques, was used in one study 
(Richardson et al., 2012). Respondents were asked to allocate a set budget to one of the 
four patients (all of whom were the same age and faced immediate death without 
treatment), which would have the effect of extending their lives by 12, 8, 6 or 4 years, 
respectively. After allocating the first budget, they were then given a second budget (of 
the same size and with the same life-extending effects) to allocate in addition to the 
ILUVW7KHSURFHGXUHZDVUHSHDWHGWLPHV5HVSRQGHQWV¶DOORFDWLRQVJDYHDQLQGLFDWLRQ
of whether they sought to maximise the number of years gained or to sacrifice overall 
gains by giving priority to the patient with the shortest life expectancy. 
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Another less established approach (in the field of health economics, at least) ± Q 
methodology (Watts and Stenner, 2012) ± was used in two studies (McHugh et al., 
2015; Wouters et al., 2017). Q methodology combines qualitative and quantitative 
methRGVWRVWXG\SHRSOH¶VVXEMHFWLYHRSLQLRQVYDOXHVDQGEHOLHIV%DNHUet al., 2006). 
Respondents in each study were presented with a set of statements describing views 
relating to the provision of end-of-life treatments. Following a structured process, they 
were asked to sort and position the statements on a response grid depending on 
whether they agreed with, disagreed with or were neutral towards them. They were then 
asked to articulate their views and to comment on statements that had been placed in 
the extremes of the grid. The researchers used factor analysis to identify underlying 
SDWWHUQVLQWKHUHVXOWLQJµ4VRUWV¶ 
Four studies employed the willingness-to-pay method (Shiroiwa et al., 2010; Shiroiwa et 
al., 2013; Pinto-Prades et al., 2014; Pennington et al., 2015), in which respondents were 
asked whether and how much they would be willing to pay, from their own pocket, for a 
given improvement in health or life extension ± or in the case of Pinto-Prades et al. 
(2014), for a specified chance of improvement. Respondents were generally expected to 
WDNHDQµRZQKHDOWK¶SHUVSHFWLYHLHWRLPDJLQHWKDWWKH\ZHUHWKHEHQHILFLDULHVRIWKH
treatment on offer) when completing the willingness-to-pay tasks. The other studies 
HPSOR\HGDµVRFLDOGHFLVLRQ-PDNHU¶SHUVSective whereby respondents were expected to 
make choices that they considered most appropriate and acceptable for society rather 
than those guided purely by self-interest. One study employed both an own health 
perspective, in willingness-to-pay tasks, and a social decision-maker perspective, in 
person trade-off tasks (Pinto-Prades et al.$QRWKHUVWXG\H[DPLQHGUHVSRQGHQWV¶
willingness-to-pay for life extensions not only for themselves but also for a family 
member (via an out-of-pocket payment) and for an unidentified member of society (via 
a tax increase) (Shiroiwa et al., 2010). 
One study compared two operationalisations of the social decision-maker perspective, 
asking half of the respondents to adopt the role of a decision-maker and assigning the 
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oWKHUKDOIWRDµYHLORILJQRUDQFH¶FRQGLWLRQ'RODQDQG&RRNVRQ,Qone of the Q 
methodology studies, the vast majority of statements presented were framed in a 
manner consistent with a social decision-maker perspective, though a few referred to the 
UHVSRQGHQW¶VRZQKHDOWKRUVLWXDWLRQ± IRUH[DPSOH³,ZRXOGQ¶WZDQWP\OLIHWREH
extending just for the sake of it ± MXVWNHHSLQJEUHDWKLQJLVQRWOLIH´0F+XJKet al., 
2015).  
Fourteen studies (60.9%) used modes of administration that required respondents to 
complete the tasks without an interviewer or moderator present to provide guidance. 
With one exception (Baker et al., 2010), the DCE studies were all administered via 
internet surveys, most likely due to the ease of obtaining large samples with this mode. 
There has been a shift towards computer-based survey administration over time ± the 
review included only four studies published since 2005 which did not use either an 
internet survey or computer-assisted personal interview approach. 
Visual aids were used by 10 studies (43.5%), including all of the DCE studies. Thirteen 
studies (56.5%) permitted respondents to express indifference between or assign equal 
value to the alternatives presented. Fourteen studies (60.9%) reported that their design 
had been informed by piloting. 
In each study, with the exception of the Q methodology studies, the size of the health 
gain was controlled for either in the design (e.g. by presenting equal-sized gains for all 
candidate recipients) or in the analysis. 
Samples 
Most of the studies used general public samples, though the extent to which the samples 
were representative of the relevant populations was mixed. McHugh et al. (2015) used a 
purposive sample comprising data-rich individuals (that is, individuals expected to have 
µULFKVWURQJDQGGLIIHUHQWYLHZV¶RQWKHWRSLFZLWKGLIIHUHQWW\SHVRIH[SHULHQFHVRU
expertise in end-of-life in a professional or personal capacity. Wouters et al. (2017) 
included 10 respondents identifying as cancer patients or survivors in their sample. 
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Skedgel et al. (2015) and Kwon et al. (2017) both surveyed a small number of decision-
makers  with the aim of contrasting their responses with those of the general public. 
Stolk et al. (2005) used a convenience sample consisting of students, researchers and 
health policy makers ± all of whom had some level of expertise in the topic of health care 
priority-setting.  
The samples ranged from 23 individuals recruited from a single small city (Dolan and 
Shaw, 2004) to 17,657 individuals recruited from nine different countries (Pennington et 
al., 2015). The seven largest-VDPSOHVWXGLHVQDOOUHFUXLWHGUHVSRQGHQWVIURP
online panels. 
End-of-life definitions 
Nine articles (39.1%) explicitly mentioned end-of-life, or some synonym for end-of-life, 
in the stated study objectives. Of the remaining studies, some included end-of-life 
amongst several prioritisation criteria examined (e.g. Linley and Hughes, 2013), whilst 
others sought to answer an altogether different research question but happened to 
provide evidence relevant to end-of-life-related preferences indirectly (e.g. Richardson et 
al., 2012). In the latter cases, preferences regarding end-of-life were inferred by 
extracting the results that could be used to draw conclusions about the values of a given 
gain for patients with different life expectancies (occasionally making calculations beyond 
those presented in the journal articles as necessary). End-of-life was most commonly 
pUHVHQWHGLQWHUPVRISDWLHQWV¶µOLIHH[SHFWDQF\¶RUµUHPDLQLQJOLIH\HDUV¶LIWKH\GLGQRW
receive the treatment, health care or transplant on offer. Other terms used included 
µIXWXUH\HDUV¶µXUJHQF\¶µIDWDOGLVHDVH¶DQGµLPPLQHQWGHDWK¶ 
A wide range oIOHYHOVIRUWKHµOLIHH[SHFWDQF\ZLWKRXWWUHDWPHQW¶DWWULEXWHZKHUH
applicable) was used. Some studies, none of which explicitly set out to examine 
preferences related to end-of-life, asked respondents to consider scenarios where 
patients would die immediately in absence of treatment, which meant in effect that their 
life expectancy without treatment was zero. In two studies (Stolk et al., 2005; Baker et 
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al., 2010LQIRUPDWLRQRQWKHSDWLHQWV¶OLIHH[SHFWDQF\ZDVQRWSUHVHQWHGGLUHFWO\EXW
could be calculated using the attributes that were included. 
Most of the studies presented at least one alternative in which the patient or patient 
group would live for less than two years without treatment, which would make them 
potentially eligible for special consideUDWLRQXQGHU1,&(¶VFULWHULD1,&( 
Comparators and other attributes examined 
In the majority of studies, the key comparison ± at least for the purposes of this review 
± was between an alternative describing a short, fixed amount of remaining life without 
treatment and one or more alternatives describing longer, fixed amounts of remaining 
life without treatment. Three studies, all of which applied the willingness-to-pay method, 
used different types of comparators (Shiroiwa et al., 2013; Pinto-Prades et al., 2014; 
Pennington et al., 2015). These studies all included scenarios involving temporary 
quality-of-life ORVVHVDQGVRXJKWUHVSRQGHQWV¶ZLOOLQJQHVV-to-pay to avoid those losses. 
One of the three studies also included a scenario involving a life extension at the end of 
WKHUHVSRQGHQW¶VRZQVWDWHGOLIHH[SHFWDQF\DQGDQRWKHULQYROYLQJVSHQGLQJWLPHLQD
coma (Pennington et al., 2015).  
While several studies included attributes relating to quality-of-life gains, only three 
explicitly tested and reported whether respondents preferred quality-of-life 
improvements or life extensions for end-of-life patients (Pinto-Prades et al., 2014; Shah 
et al., 2014; Shah et al., 2015a). Other studies collected the data required to make such 
comparisons possible but did not focus on quality-of-life in the published articles. 
Ten studies (43.5%) purposely included information about age, thereby providing 
evidence on interactions and trade-offs EHWZHHQUHVSRQGHQWV¶SUHIHUHQFHVUHJDUGLQJDJH
and regarding end-of-life. One study (5%) attempted to control for time-related 
preferences by including questions designed to identify whether any observed preference 
for treating patients with shorter life expectancy is driven by a preference for the 
benefits of treatment to occur sooner rather than later (Shah et al., 2014).  
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Findings of the studies 
Evidence consistent with an end-of-life premium 
Eight studies (34.8%) report evidence of support for placing greater weight on a unit of 
health gain for patients with relatively short life expectancy than on that for other types 
of patients. Their findings are summarised briefly below (presented in chronological 
order). 
Stahl et al. (2008) report that respondents preferred treating the patient who was closer 
to death until the difference in life expectancy was less than 1.1 months (beyond which 
they showed no preference for the patient with shorter life expectancy). They also report 
that when one patient was set to gain a shorter life extension than another, the former 
needed to have a shorter life expectancy without treatment in order to be given priority 
overall (up to a threshold). 
Shiroiwa et al. (2010) report that in all six countries examined, higher willingness-to-pay 
values were observed in scenarios where respondents had zero years of life expectancy 
than in scenarios where they had five years of life expectancy.  
Lim et al. (2012) report that higher priorities were given to patients with less remaining 
life, noting that that respondents overall were willing to give up a 0.39 QALY gain in 
order to treat the patient whose life expectancy without treatment was one level (usually 
five years) lower. 
Pinto-Prades et al. (2014) report that six- or 18-month life extensions for end-of-life 
patients were valued more highly than temporary quality-of-life improvements for non-
end-of-life patients that were equivalent in terms of the number of QALYs gained. They 
note that this result was observed in both the willingness-to-pay and the person trade-
off surveys, though the patterns of responses differed across the two methods. 
Rowen et al. (2016a) report results that showed support for an end-of-life premium 
across different regression models, with evidence of a preference for treating patients 
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with shorter life expectancy without treatment. However, the responses to their follow-
up (attitudinal, non-choice-based) questions appear to contradict this finding. 
Shah et al. (2014) report that the majority of respondents chose to give a six-month life 
extension to the patient with one year left to live without treatment rather than to the 
patient with 10 years left to live without treatment. However, they also noted that a 
non-trivial minority of respondents expressed the opposite preference.  
Pennington et al. (2015) report that the mean and median willingness-to-pay values for 
RQH4$/<ZRUWKRIOLIHH[WHQVLRQDFKLHYHGLQWKHVFHQDULRRIµLPPLQHQWSUHPDWXUHGHDWK
IURPDOLIHWKUHDWHQLQJGLVHDVH¶ZHUHFRQVLGHUDEO\ODUJHUWKDQWKRVHIRUDQHTXDO-sized 
JDLQDFKLHYHGDWWKHHQGRIUHVSRQGHQWV¶VHOI-predicted life expectancy. 
Kwon et al. UHSRUWWKDWµGLVHDVHVHYHULW\¶GHILQHGLQWHUPVRIWKHOLNHOLKRRGRI
dying within five years) was one of the three most preferred criteria for reimbursement 
decisions, alongside clinical benefits and cost-effectiveness. 
Evidence not consistent with an end-of-life premium 
Eleven studies (47.8%) report evidence that people do not wish to place greater weight 
on a unit of health gain for patients with relatively short life expectancy than on that for 
other types of patients.  
Dolan and Shaw (2004) report that the majority of respondents chose to give priority to 
the patient with the longest life expectancy without a kidney transplant and who stood to 
gain the most from receiving the transplant. When it was later revealed that the end-of-
life patient was the oldest of the six candidate recipients, none of the respondents chose 
to give the transplant to that patient. 
Dolan and Tsuchiya (2005) report that respondents priority ranked end-of-life patients 
lower than corresponding non-end-of-life patients for all levels of age and past health. 
They also note that the coefficient for future years (life expectancy without treatment) as 
a main effects variable was not statistically significant. 
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Stolk et al. UHSRUWSULRULW\UDQNLQJVEDVHGRQUHVSRQGHQWV¶FKRLFHVLQSDLUHG
comparison tasks) of 10 conditions that correlated poorly and non-significantly with the 
WKHRUHWLFDOUDQNLQJLPSOLHGE\DµSULRULW\WRVKRUWHUOLIHH[SHFWDQF\¶DSSURDFK2WKHU
theoretical rankings (severity, fair innings, proportional shortfall) were all significantly 
correlated with the observed ranking. Respondents were less concerned about life-
threatening conditions for the elderly than prospective health theories that ignore the 
past (i.e. age) would have predicted. 
Abel Olsen (2013) reports evidence of strong support for the fair innings argument, 
QRWLQJWKDWUHVSRQGHQWV¶FKRLFHVZHUHQRWDIIHFWHGE\GLIIHUHQFHVLQSDWLHQWV¶UHPDLQLQJ
lifetime without treatment. 
Linley and Hughes (2013) report that, when faced with a choice between treating one 
patient group with a life expectancy of 18 months and another patient group with a life 
expectancy of 60 months, about two-thirds of respondents opted not to allocate more 
resources to the end-of-life group. The most popular choice was to allocate an equal 
amount of funding to both groups. 
Shiroiwa et al. (2013) report that the proportions of respondents willing to pay an initial 
bid value for gains worth 0.2 or 0.4 QALYs were consistently lower in end-of-life 
scenarios than in non-end-of-life scenarios. Further, the average willingness-to-pay per 
QALY values observed in the end-of-life scenarios were generally lower than in the non-
end-of-life scenarios. 
Shah et al. (2015a) report a statistically significantly negative coefficient for the life 
expectancy without treatment variable, but noted that it was very small in magnitude 
compared to the health gain coefficients and had very little impact on the choices made 
by respondents. An end-of-life dummy variable defined purely in terms of life expectancy 
without treatment was found to have a small and non-significant coefficient. 
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Skedgel et al. (2015) report evidence of statistically significant and negative (positive) 
welfare effects associated with prioritising patients with the shortest (longest) level of 
initial life expectancy. 
Rowen et al. (2016b) report an approximately equal split between choosing to treat a 
patient group with a life expectancy of five years and choosing to treat another patient 
group with a life expectancy of 10 years. Tests of association conducted by the authors 
indicate that this result did not depend on the mode of administration, wording of the 
question, or use of visual aids.   
Chim et al. (2017) report that, when faced with a choice similar to that in Linley and 
Hughes (2013) above (between treating one patient group with a life expectancy of 18 
months and another patient group with a life expectancy of 60 months), about three-
quarters of respondents opted not to allocate more resources to the end-of-life group. 
Consistent with Linley and Hughes (2013), the most popular choice was to allocate an 
equal amount of funding to both groups. 
Wouters et al. UHSRUWWKDWWKUHHµYLHZSRLQWV¶VKDUHGSHUVSHFWLYHVHPHUJHGIUom 
their data, but in none of those viewpoints did they find direct support for making a 
special case for life-extending treatments for end-of-life patients. 
Studies reporting mixed or inconclusive evidence 
Four studies (20%) reported evidence that cannot easily be interpreted as being clearly 
consistent or inconsistent with an end-of-life premium. This was either because of 
heterogeneous preferences or because the observed results were not sufficiently robust. 
Dolan and Cookson (2000) report that when asked to choose between giving a 10-year 
life extension to one patient group with 10 years of life expectancy without treatment 
and another with 30 years of life expectancy, 2% of respondents chose the latter; 50% 
chose the former; and 48% gave the same priority to both groups. 
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Baker et al. (2010) assessed preferences for different scenarios relative to a reference 
scenario of treating 40 year old patients expected to die at 60 years with a 0.7 quality-
of-life loss without treatment. They report that in scenarios which were purely life-saving 
(i.e. involving immediate death without treatment), a preference was observed for 
treating patients aged 10 years relative to the reference scenario (controlling for the size 
of QALY gain). For other ages (1, 40 or 70 years), the reference scenario was preferred 
to the life-saving treatments. Similarly, life-saving treatments for 10 year old patients 
were preferred to treatments (offering the same QALY gains) for 10 year old patients 
who would not die immediately if left untreated, whilst the opposite was observed for 
patients of other ages. 
Richardson et al. (2012) report that the majority of respondents did not behave in a 
QALY-maximising manner, with 69% allocating one of their first four budgets to the 
patient who stood to gain least (a four-year life extension) rather than giving that 
budget to the patient who stood to gain most (12-year life extension). The authors note 
that the average respondent allocated resources in such a way that 62.6% of possible 
gains in life years were achieved, with 37.4% of gains sacrificed to achieve sharing. In 
their regression models, life expectancy is a dominating variable ± across all choices, the 
JUHDWHUDJLYHQSDWLHQW¶VOLIHH[SHFWDQF\WKHVPDOOHUWKHSUREDELOLW\RIWKDWSDWLHQW
receiving resources (i.e. further life extensions).  
McHugh et al. LGHQWLILHGWKUHHµIDFWRUV¶VKDUHGSHUVSHFWLYHVLQWKHLUDQDO\VLV
7KHILUVWIDFWRUGHVFULEHVWKHYLHZWKDWVRFLHW\¶VLQWHUHVWVDUHEHVWVHUYHGE\VHHNLQJWR
maximise population health, DQGWKDW³WHUPLQDOLOOQHVVVKRXOGQRWEHWUHDWHGDVDVSHFLDO
FDVH´S7KHVHFRQGIDFWRUHPSKDVLVHVSDWLHQWFKRLFHDQGWKHULJKWWROLIH-extending 
treatment for patients who want it, though this right may apply to non-end-of-life as well 
as end-of-life conditions. The third factor permits cases where special value is placed on 
extending the life of end-of-life patients, but this value is not unconditional and must be 
ZHLJKHGXSDJDLQVWRSSRUWXQLW\FRVWV7KHILQGLQJVGHPRQVWUDWHWKHµSOXUDOLW\RIYLHZV¶ 
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within society and the authors highlight the problems associated with determining policy 
based on simple majority votes. 
Table 3 compares the distribution of selected variables of interest among studies that 
report evidence consistent with an end-of-life premium with those among studies that do 
not. 
<Table 3 here> 
Other findings of relevance 
Most of the studies did not examine or report explicitly whether quality-of-life 
improvements or life extensions for end-of-life patients were preferred, though in some 
cases it would have been possible to examine this given the nature of the data collected. 
Two studies reported that respondents favoured quality-of-life improvements (Pinto-
Prades et al., 2014; Shah et al., 2014); and one study reported that respondents 
favoured life extensions (Shah et al., 2015a) ± controlling for the size of health gain in 
all cases. 
The majority of studies included patient age in the study design. In some cases age was 
one of several prioritisation criteria being examined; in other cases, the researchers 
ZHUHVHHNLQJWRH[DPLQHZKHWKHUUHVSRQGHQWV¶HQG-of-life-related preferences were 
influenced by the ages of the patients. The findings of two studies suggest that 
respondents become less concerned about the number of remaining life years when the 
patients in question are relatively old (Dolan and Shaw, 2004; Stahl et al., 2008). One 
study did not find that concern about age is a motivating factor for giving priority to the 
treatment of end-of-life patients (Shah et al., 2014), though the range of ages presented 
was narrow (nine years). Several studies reported evidence that respondents gave 
priority to younger patients, often without making an explicit link between age-related 
preferences and end-of-life-related preferences (Dolan and Cookson, 2000; Dolan and 
Tsuchiya, 2005; Stolk et al., 2005; Baker et al., 2010; Abel Olsen, 2013; Skedgel et al. 
2015). 
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Time-related preferences were mentioned in only a few of the studies. One study 
reported evidence that patients who have only just learned their prognosis are given 
priority over those who have known about their prognosis for some time, controlling for 
life expectancy (Shah et al., 2014). Another study interpreted differences between 
willingness-to-pay values in end-of-life and non-end-of-life scenarios in terms of time 
preference, and used the data to estimate discount rates (Shiroiwa et al., 2010). Three 
VWXGLHVDFNQRZOHGJHGWKDWWKHLUILQGLQJVPD\KDYHEHHQLQIOXHQFHGE\UHVSRQGHQWV¶WLPH
preference or that applying a positive discount rate in the analysis would have led to 
slightly (albeit not qualitatively) different results (Richardson et al., 2012; Pennington et 
al., 2015; Shah et al., 2015a).  
Two studies reported evidence that older respondents were more likely than average to 
PDNHFKRLFHVEDVHGRQSDWLHQWV¶OLIHH[SHFWDQF\ZLWKRXWWUHDWPHQW'RODQDQG7VXFKL\D
2005; Stahl et al., 2008). One of the willingness-to-pay studies reported that older age 
was associated with lower valuation for life extensions in the own terminal illness 
scenario (Pennington et al., 2015). Other background characteristics found to be 
DVVRFLDWHGZLWKUHVSRQGHQWV¶SULRULW\-setting preferences were: education (Dolan and 
Tsuchiya, 2005; Shiroiwa et al., 2010); employment status (Dolan and Tsuchiya, 2005); 
health status (Pennington et al., 2015); health history of family members (Stahl et al., 
2008); and household income (Shiroiwa et al., 2010). However, the majority of studies 
either did not observe any associations between background characteristics and 
preferences or did not report any such analysis. McHugh et al. (2015) found that none of 
the academic researchers in their sample helped to define the shared account most 
closely related to support for an end-of-life premium, though the authors warn against 
making generalisations based on qualitative samples. 
Discussion 
Twenty-three empirical studies that inform the research question of whether members of 
the public wish to place greater weight on a unit of health gain for end-of-life patients 
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than on that for other types of patients were identified and reviewed. The number of 
studies addressing this topic has been growing ± several were initiated following (and 
UHIHUH[SOLFLWO\WRWKHLVVXLQJRI1,&(¶Vend-of-life policy in January 2009. Many of the 
studies originated in the UK, which is unsurprising given the policy interest in NICE (an 
agency which make recommendations on the use of health technologies in England). The 
majority of the studies reviewed used a preference elicitation technique that can be 
GHVFULEHGDVDµFKRLFHH[HUFLVH¶ZLWKDQLQFUHDVLQJQXPEHUVSHFLILFDOO\DSSO\LQg the DCE 
method. This reflects the growing popularity of the method in applied health economics 
research (de Bekker-Grob et al., 2012; Clark et al., 2014), particularly in the field of 
health care priority-setting (Whitty et al., 2014). DCEs are considered to enjoy a strong 
theoretical basis (Lancsar and Donaldson, 2005) and there is evidence that the method 
is feasible, flexible and capable of presenting choices that are relevant to respondents 
(Ryan and Gerard, 2003).  
The primary finding of the review is that the existing evidence is mixed, with eight 
studies that report evidence consistent with a premium for end-of-life treatments and 11 
studies that do not. Reviews of severity-related preferences more generally have been 
able to reach more decisive conclusions ± Shah (2009) and Nord and Johansen (2014) 
both report an overall preference for giving higher priority to those who are severely ill ± 
but as mentioned above the studies reviewed typically focused on severity in terms of 
quality-of-life, not length of life. Comparing the findings of the reviews of severity with 
those of the present review suggests that people are more likely to be concerned about 
treating patients with poor quality-of-life than with treating patients with short life 
expectancy. However, this supposition is not supported by individual studies that 
examined both simultaneously ± Stahl et al. (2008), Shah et al. (2015a) and Rowen et 
al. (2016a) all report stronger support for giving priority to treating patients with 
relatively short life expectancy than to treating those with relatively poor quality-of-life, 
controlling for the size of health gain.  
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The evidence on whether quality-of-life improvements or life extensions for end-of-life 
patients is also mixed, with two studies reporting evidence of an overall preference for 
quality-of-life improvements, and one study reporting the opposite. It is noteworthy that 
the current NICE policy involves giving greater weight to life-extending but not to 
quality-of-life-improving treatments for those at the end-of-life. There is little evidence 
to suggest that such a policy is consistent with public preferences. 
The overall findings of studies were summarised by assigning each to one of three 
categories: (1) consistent with an end-of-life premium; (2) not consistent with an end-
of-life premium; and (3) mixed or inconclusive evidence. In absence of a clear definition 
RIZKDWFRXQWHGDVµVXSSRUW¶WKLVH[HUFLVHLQYROYHGDGHJUHHRIVXEMHFWLYHMXGJHPHQW,W
is rarely the case in stated preference studies that a unanimous preference is observed. 
There is usually a split in opinion, and a judgement then needs to be made about 
whether the minority view is held by a sufficiently large number of respondents (or held 
sufficiently strongly) so as to conclude that the evidence is inconclusive overall. As far as 
SRVVLEOHWKHVWXG\DXWKRUV¶RZQFRQFOXVLRQVZHUHXVHGDVDJXLGH7KLVZDVQRWDOZD\V
possible, since some studies did not set out to examine end-of-life-related preferences 
directly and further subjective interpretation of the reported results was required. In 
cases where there was uncertainty about the conclusions of a given study, the 
corresponding author was contacted to check that they agreed with the proposed 
summary and categorisation of their findings.  
The heterogeneity of preferences held by the general population is highlighted by 
McHugh et al. (2015) and Wouters et al. (2017), who each identified three distinct 
shared perspectives in their respective datasets. Other studies similarly identified 
multiple subgroups within their samples whose response patterns imply very different 
views about the value of end-of-life treatments (e.g. Pinto-Prades et al., 2014; Shah et 
al., 2015a). Given these findings, it is perhaps not surprising that this review has been 
unable to establish whether or not the overall evidence available in the literature is 
consistent with an end-of-life premium. 
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Majoritarian decision rules are common in politics and policy making, with most elections 
and referendums in modern western democracies being decided by majority rule. 
However, such approaches are criticised for failing to achieve outcomes that represent 
the views of all sections of society in a representative manner (Mill, 1861). A 
hypothetical example of a study that would be problematic to categorise based on 
majority rule is one in which a slight (but statistically significant) majority of respondents 
express weak support for an end-of-life premium and a sizeable minority strongly 
disfavour an end-of-life premium. Many of the studies in this review did not examine 
strength of preference at the individual respondent level and were not designed in such a 
ZD\WKDWQXDQFHVDQGFDYHDWVUHJDUGLQJUHVSRQGHQWV¶VWDWHGSUHIHUHQFHVFRXOGEH
captured. The normative basis for specifying a measure of average or overall preference 
in social choices is unclear ± in the context of aggregating preferences regarding health 
states, Devlin et al. (2017) conclude that there are no strong grounds for favouring any 
one approach. 
Table 3 shows how studies that report evidence consistent with an end-of-life premium 
compare to those that do not. The number of studies included in the review is 
insufficient to permit meaningful testing of statistical associations, so any trends 
observed should be interpreted with caution. Nevertheless, there is weak evidence that 
studies were more likely to report evidence consistent with an end-of-life premium if 
they: used the willingness-to-pay method; allowed indifference to be expressed; or used 
visual aids. Each of these variables is discussed in turn below. It is acknowledged that 
the following sub-sections ± particularly those relating to indifference options and visual 
aids ± involve a degree of subjective judgement and speculation on the part of the 
authors. 
Choice of method and perspective 
Most of the studies in this review asked respondents to adopt a social decision-maker 
perspective ± that is, they were asked to consider questions typically of concern to a 
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health care decision-maker (such as whether one patient group or another should 
receive higher priority in the face of scarce shared resources) and to answer those 
questions based on what they consider to be appropriate and acceptable for society. The 
respondent (acting as decision-maker for the purpose of the study) would not 
necessarily expect to benefit personally from their choices. The four studies that used 
the willingness-to-pay approach, on the other hand, generally asked respondents to 
adopt an individual or own health perspective ± that is, they were asked how much they 
would pay (from their own pocket) for a given improvement in their own health. This 
method is consistent with the welfarist view that confines the evaluative space to 
individual utility only ± WKHµJRRGQHVV¶RIDSROLF\FDQEHMXGged solely on the basis of the 
utility gains and losses achieved by individuals affected by that policy (Brouwer et al., 
2008).  
Three of the four willingness-to-pay studies report evidence consistent with an end-of-
life premium, based on higher average willingness-to-pay values for a life extension in 
an end-of-life scenario than for a similar gain (e.g. worth the same number of QALYs) in 
a non-end-of-life situation. However, and as acknowledged by Pennington et al. (2015), 
willingness-to-pay valuations made by individuals facing the prospect of imminent death 
can be expected to be high because the opportunity costs in those circumstances are low 
or non-existent. Other than the ability to leave a legacy, money is arguably of no use to 
individuals when they DUHGHDG7KLVLVRIWHQUHIHUUHGWRDVWKHµGHDG-DQ\ZD\¶HIIHFW
ZKHUHE\DQLQFUHDVHLQDQLQGLYLGXDO¶VPRUWDOLW\ULVNUHGXFHVWKHLUH[SHFWHGPDUJLQDO
utility of wealth (thereby increasing their willingness-to-pay) since the marginal utility of 
wealth when alive is greater than the marginal utility of wealth when dead (Pratt and 
Zeckhauser, 1996). It is therefore understandable and perhaps consistent with utility-
maximising behaviour for individuals nearing their end-of-life to be willing to spend most 
or all of the money they have on extending their life, even if the utility gains from the 
life extension are small. If such willingness-to-pay values are then used to inform 
decisions about how to spend a common pool of funding that has been raised from 
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members of the public (many of whom will not be at their end-of-life), then the 
opportunity cost of expenditure on end-of-life treatments will be higher as it would result 
in foregoing spending on other treatments. It may therefore be considered inappropriate 
to use willingness-to-pay values elicited from an individual perspective to inform society-
level decision-making. It should be noted, however, that Shiroiwa et al. (2010) observed 
KLJKHUYDOXHVIRUJDLQVDFFUXLQJWRUHVSRQGHQWV¶IDPLO\PHPEHUVDQGWRXQLGHQWLfied 
members of society than those accruing to the respondents themselves in five of the six 
countries studied. The authors suggest that this result may reflect altruistic preferences. 
When developing the inclusion criteria for this review, it was deemed appropriate to 
include own health perspective studies that clearly sought to inform health care priority-
setting policies. Some own health perspective studies that appeared to report results of 
potential relevance to the overall research question were nevertheless excluded on the 
basis that they did not clearly seek to inform health care priority-setting policies (e.g. 
Kvamme et al., 2010). An alternative approach would have been to restrict the review to 
studies adopting a social decision-maker perspective. One of the studies that used the 
willingness-to-pay method would continue to be included in the review on the basis that 
it also reported preferences obtained using person trade-off tasks undertaken from a 
social decision-maker perspective (Pinto-Prades et al., 2014). The study by Shiroiwa et 
al. (2010) would be excluded on the basis that it employed a social decision-maker 
perspective in only one task, involving a scenario describing imminent death, so 
comparisons between end-of-life and non-end-of-life social decision-maker valuations 
would not be possible. Applying such a restriction would result in a slightly different 
balance of findings across the studies: of the studies that would remain, five report 
evidence consistent with an end-of-life premium and eight do not.  
Inclusion of indifference options 
Studies that offered respondents the opportunity to express indifference between the 
alternatives on offer were more likely to report evidence consistent with an end-of-life 
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premium than those that did not. The nature of the indifference options available 
GLIIHUHGDFURVVVWXGLHV,QWKHFKRLFHH[HUFLVHVWXGLHVRSWLRQVVXFKDVµ&DQ¶WGHFLGH¶
(Stahl et al.DQGµ,KDYHQRSUHIHUHQFH¶6KDKet al., 2014) were presented. In 
the willingness-to-pay studies, respondents could express indifference by stating the 
same value for two or more different gains. In the budget allocation study, respondents 
could choose to split resources evenly between the two recipient groups. In the Q 
methodology studies, respondents were required to position some of the statements in 
such a way that implied neither agreement nor disagreement.   
7KHZD\LQZKLFKLQGLIIHUHQFHRSWLRQVDUHIUDPHGFDQDIIHFWUHVSRQGHQWV¶ZLOOLQJQHVVWR
choose those options ± for example, Shah and Devlin (2012) reported that respondents 
showed an attraction to a 50:50 split when asked to allocate a budget between two 
SDWLHQWJURXSVEXWDQDYHUVLRQWRDQµ,KDYHQRSUHIHUHQFH¶RSWLRQLQDFKRLFHH[HUFLVH
involving the same two groups. This finding is supported by those of the present review 
± the two budget allocation studies both found that a 50:50 split was the most popular 
RSWLRQ,WPD\EHWKDWUHVSRQGHQWVFRQVLGHUDVSOLWEXWQRWDQµ,KDYHQR
SUHIHUHQFH¶UHVSRQVHWREHDOHJLWLPDWHFKRLFHZKHQ they find it difficult to choose 
between two options. Alternatively, they may be concerned about the implications of 
expressing indifference in a choice exercise ± for example, they might be under the 
impression that failing to choose means that neither patient would receive the treatment 
on offer.  
When respondents are indifferent between the available options but no indifference 
option is available, they are forced to make a choice in order to proceed. In principle, 
these respondents should make their choices at random, which will tend to result in a 
roughly even split between the available options in the choice data. In practice, 
respondents may pursue an alternative choice strategy. For example, when faced with a 
choice between treating an end-of-life patient and a non-end-of-life patient, a 
respondent may anticipate other respondents choosing to treat the end-of-life patient 
but may themselves consider both patients to be equally deserving of treatment. If this 
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respondent wishes that both patients should be given an equal opportunity to be treated, 
they may then express a preference for treating the non-end-of-life patient (to 
counteract the choices they anticipate the other respondents making). This increases the 
likelihood of the study failing to find an overall preference for treating the end of patient. 
Evidence of such response behaviour has been discussed by Shah et al. (2015b).  
It is common for DCEs and studies using internet surveys ± both of which are becoming 
increasingly popular in this field ± not to include opt-out or indifference options. For 
DCEs, best practice guidelines advise that indifference options are often inappropriate as 
they can have implications for the experimental design and lead to the censoring of data 
(Bridges et al., 2011). For internet surveys, which are sometimes viewed with suspicion 
GXHWRFRQFHUQVDERXWUHVSRQGHQWV¶DWWHQWLYHQHVVLQGLIIHUHQFHRSWLRQVDUHRIWHQDYRLGHG
on the grounds that they will be used a default choice, thus providing respondents with a 
way to avoid taking time to make difficult decisions. If studies are less likely to detect 
support for an end-of-life premium if they do not include an indifference option, and if 
the trend for studies not to include an indifference option continues, then it can be 
expected that fewer studies will report evidence consistent with an end-of-life premium 
going forward.  
Use of visual aids 
The use of visual aids appears to be increasing. Most of the studies published since 2014 
included diagrams designed to help respondents make sense of the (often complex) 
choice tasks. These often took the form of figures depicting quality-of-life on one axis 
and length of life or time on the other. Visual aids were used in all five DCE studies 
reviewed, and in the majority of studies administered using a computer-based approach. 
Studies that used visual aids were more likely to report evidence consistent with an end-
of-life premium than those that did not. One possible explanation is that very short 
amounts of time (in most studies respondents were presented with scenarios in which at 
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least one patient had less than 12 months left to live) appear starker and more dramatic 
when presented graphically than when described verbally.  
It has been argued that graphs may not be the best way to present scenario information 
to survey respondents due to concerns that they unintentionally lead to different 
respondents interpreting the information in different ways (van de Wetering et al., 
2015). For example, when faced with diagrams in which better quality-of-life and longer 
life expectancies are represented by larger areas, some respondents may 
(subconsciously or otherwise) be attracted to the larger areas and therefore to the 
alternatives depicted by diagrams showing longer life expectancies.  
Such framing effects are clearly a matter of concern, particularly in studies where no 
interviewer is present, since the opportunities for instructing and debriefing respondents 
are very limited. This makes it difficult to know for certain the extent to which the choice 
GDWDWUXO\UHIOHFWWKHUHVSRQGHQWV¶EHOLHIVDQGSUHIHUHQFHVRUZKHWKHUWKHUHVSRQGHQWV
interpreted and answered the questions as the researcher had intended them to. 
However, this concern is not restricted to the use of visual aids. One possibility is that 
respondents being presented with two or more hypothetical patients may mistakenly 
interpret the task as asking them which patient they would prefer to be in the position of 
rather than which patient they consider to be more deserving of treatment. It is not clear 
that such a misinterpretation would be more likely to occur in a survey using a 
combination of text and graphical descriptions than in one using only text descriptions. 
Indeed, if the issue is that respondents being presented with complex choice tasks do 
not always understand what is being asked of them, it seems intuitive to give them 
more, rather than less, assistance. 
Further, if the use of visual aids encourages respondents either to choose the patient 
they would prefer to be in the position of, or to choose the alternative associated with 
larger areas, then this would in most cases result in them being more likely to choose to 
treat patients with longer rather than shorter life expectancies. This is inconsistent with 
 30 
 
the finding of this review that studies using visual aids were more likely to report 
evidence consistent with an end-of-life premium than those that did not. One study that 
XVHGWZRGLIIHUHQWTXHVWLRQIUDPHVWRXQGHUVWDQGUHVSRQGHQWV¶SUHIHUHQFHVUHJDUGLQJ
end-of-life found that many respondents expressed support for prioritising life-extending 
end-of-life treatments in the DCE tasks (which used visual aids) (Rowen et al., 2016a). 
However, the same respondents then gave responses to more direct attitudinal 
questions (which did not use visual aids) that suggest that they did not believe that the 
NHS should give priority to such treatments. Furthermore, the one study that actively 
set out to examine the impact of visual aids found that the propensity to choose to treat 
the patient group with shorter life expectancy was unaffected by whether diagrams were 
used to illustrate the information (Rowen et al., 2016b).  
The findings of this review may suggest that the likelihood of a study providing evidence 
consistent with an end-of-life premium is linked to the choice of perspective and to 
whether indifference options and visual aids were used. However, it should also be noted 
that conflicting results were reported by two studies that did not differ in these respects. 
Shah et al. (2015a) and Rowen et al. (2016a) both used the DCE method with forced-
choice tasks supported by visual aids (indeed, Shah et al. acknowledge that they based 
their design on that of the Rowen et al. study, using very similar graphs and text 
descriptions to present information to respondents). Both studies also used similar 
samples ± members of the UK public recruited from online panels and broadly 
representative of the general population in terms of age and gender.  
Limitations  
Some limitations of the review should be mentioned. Only one database ± the SSCI ± 
was searched. It is acknowledged that similar reviews sometimes involve searches of 
multiple databases in order to increase the likelihood of identifying relevant studies from 
a broad range of journals. However, SSCI is an interdisciplinary database covering 
around 3,000 journals from across the social sciences, including most major health 
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economics and health policy journals known to the authors. Indeed, seven of the eight 
additional studies identified through follow-up of references were published in journals 
that are indexed in SSCI.  
The review included only articles that have been published in English. Only two records 
were excluded due to publication in a language other than English, but this could be 
linked to the choices made regarding data sources and the search strategy. On a related 
note, the review was to a large extent motivated by the policy context in the UK. The 
authors of this review identify as health economics researchers based in the UK (the 
same is true of many of the authors of studies included in the review). Hence, the search 
terms considered are likely to reflect the language used by this particular subset of the 
academic community and may not be well suited for identifying, say, articles authored 
by ethicists or by researchers based in low-income countries.  
Whereas reviews of clinical trials are subject to rigorous guidance on search methods, 
data extraction and evidence synthesis (Centre for Reviews and Dissemination, 2009; 
Liberati et al., 2009), such guidance is unavailable for reviews of stated preference 
studies. Although it cannot be claimed that the review is fully exhaustive, efforts have 
been made to be explicit about the methods used and balanced in the presentation of 
findings.  
As mentioned above, a formal assessment of study quality was not undertaken due to 
the lack of a known, standardised method for doing so. Instead, publication in a peer-
reviewed journal was relied on as a proxy for quality. None of the studies included in the 
review was judged to be of such poor quality that their findings ought to be disregarded. 
However, it is acknowledged that there may be studies that are relevant to the research 
question that have not been published in a peer-reviewed journal, such as those in the 
JUH\OLWHUDWXUHIRUH[DPSOHUHSRUWVRI1,&(¶V&LWL]HQV¶&RXQFLO± see NICE, 2017) and 
working papers or theses that had not been submitted to or accepted by a journal. 
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The follow-up of reference lists of the articles whose full texts were reviewed was useful 
± eight of the 23 included articles (34.8%) were identified in this way. A further step 
would have been to search for articles that have cited those already identified, as in 
µVQRZEDOOLQJ¶RUµFLWDWLRQSHDUOJURZLQJ¶3DLVOH\.    
Gaps in the literature  
Given the possibility that the findings of stated preference studies are influenced by the 
choice of elicitation method or by characteristics of the study design, it would be 
informative for studies to use multiple methods or designs in order to test the 
robustness of their results. Most of the studies included in this review used a single 
method and design throughout. Exceptions to this include Pinto-Prades et al. (2014), 
who noted discrepancies between willingness-to-pay and person trade-off responses at 
the within-respondent level (though the same broad conclusion was reached using both 
methods); and Rowen et al. (2016b), who compared the results achieved using different 
modes of administration and question framings. A recent study by Gyrd-Hansen (2017) 
± published after the updated search for this review was undertaken ± is informative in 
this respect as it elicits end-of-life-related preferences from both an individual and a 
social decision maker perspective (it is also novel in that it compares end-of-life 
treatments to preventive interventions).  
A related issue is that few studies sought to understand whether respondents would 
DJUHHZLWKWKHUHVHDUFKHUV¶LQWHUSUHWDWLRQVRIWKHLUUHVSRQVHVWRWKHVWDWHGSUHIHUHQFH
tasks. Rowen et al. (2016a) inferred from their DCE data that there was robust and 
consistent support for an end-of-life premium. Yet when asked about the prioritisation of 
end-of-life patients more directly later in the survey, the majority of respondents 
expressed views that implied the opposite conclusion. It would be informative for 
UHVHDUFKHUVWRWHVWWKHVWDELOLW\RIUHVSRQGHQWV¶SUHIHUHQFHV± for example, by presenting 
the policy implications of their earlier choices and checking whether they agree with 
these (Whitty et al., 2014; Shah et al., 2015b). Studies applying techniques that are 
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designed to allow unexpected views to emerge, such as Q methodology (as used by 
McHugh et al. (2015) and Wouters et al. (2017)), also offer promise for researchers 
seeking to make sense of apparently inconsistent or counterintuitive preferences. 
Policy implications 
Overall, the evidence on public preferences regarding the special weighting of end-of-life 
treatments is mixed. It should also be noted, however, that the studies conducted in the 
UK have not, on the whole, reported evidence consistent with an end-of-life premium. 
This has relevance for assessing the OHJLWLPDF\RI1,&(¶VHQG-of-life policy, which was 
said to have been motivated at least in part by the views held by the population that the 
NHS serves (Rawlins et al., 2010). Based on this finding, it might be deemed appropriate 
for NICE to consider abandoning its end-of-life policy and any other mechanisms that 
relax the cost-effectiveness requirements for end-of-life treatments, on the grounds that 
the population health losses that arise due to the policy (Collins and Latimer, 2013) are 
not justified by the evidence on societal preferences. This would result in fewer 
approvals of end-of-life treatments, and therefore in reduced access to treatments for 
patients with terminal illness. In principle, of course, other, less identifiable groups of 
patients would benefit as the freed funding could be spent on health care that is more 
cost-effective and/or that the public values more. 
It may be that there are compelling arguments for retaining some form of end-of-life 
weighting irrespective of public preferences. For example, if the standard QALY approach 
± used not only by NICE but also by similar agencies in many other countries ± 
systematically underestimates the (health or non-health) benefits of end-of-life 
treatments (whether or not this is actually the case would itself need investigating), it 
may be appropriate to correct for this. An end-of-life premium may also help to 
encourage innovation, or to meet broader health system and political objectives. Finally, 
it is worth noting that once a prominent policy has been introduced, withdrawing it may 
be inherently and procedurally difficult ± a point that should be heeded by countries 
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contemplating the introduction of explicit weighting or prioritisation based on equity or 
other considerations. 
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Table 1. Summary of included studies (n=20) 1 
Authors (date) Country Sample size 
(type) 
Method a Mode of administration Summary of primary study objective(s) 
Abel Olsen (2013) NOR 503 (public) Choice Internet survey To test for support for end-of-life prioritisation and the fair 
innings approach 
Baker et al. (2010) UK 587 (public) DCE Computer-assisted 
personal interview 
To test for support for multiple prioritisation criteria 
Chim et al. (2017) AUS 3,080 (public) Budget 
allocation 
Internet survey To test for support for multiple prioritisation criteria 
Dolan and 
Cookson (2000) 
UK 60 (public) Choice Focus group (individual 
responses) 
Qualitative examination of support for multiple prioritisation 
criteria 
Dolan and Shaw 
(2004) 
UK 23 (public) Choice Focus group (individual 
responses) 
To test for support for multiple prioritisation criteria 
Dolan and 
Tsuchiya (2005) 
UK 100 (public) Choice; 
ranking  
Individual self-
completion survey 
(completed in group 
setting) 
To compare support for prioritisation according to age vs. 
prioritisation according to severity/life expectancy 
Kwon et al. (2017) ROK 300 (public); 30 
(decision-
makers) 
Analytic 
hierarchy 
process 
Non-computer-assisted 
personal interview 
To test for support for multiple prioritisation criteria 
Lim et al. (2012) ROK 800 (public) DCE Internet survey To test for support for multiple prioritisation criteria 
Linley and Hughes 
(2013) 
UK 4,118 (public) Budget 
allocation 
Internet survey To test for support for multiple prioritisation criteria  
McHugh et al. 
(2015) 
UK 61 (µdata-rich¶ 
individuals) b 
Q method Non-computer-assisted 
personal interview 
Qualitative examination of societal perspectives in relation to 
end-of-life prioritisation 
Pennington et al. 
(2015) 
Multiple 17,657 (public) WTP Internet survey To compare WTP for different types of QALY gain 
Pinto-Prades et al. 
(2014) 
SPA 813 (public) WTP; PTO Computer-assisted 
personal interview 
To test for support for end-of-life prioritisation and to compare 
support for life extensions vs. quality-of-life improvements 
Richardson et al. 
(2012) 
AUS 544 (public) Other Multiple modes: 
Internet survey and 
self-completion survey 
(postal) 
To test a technique for measuring support for health-
maximisation and health sharing 
Rowen et al. 
(2016a) 
UK 3,669 (public) DCE Internet survey To test for support for multiple prioritisation criteria 
Rowen et al. 
(2016b) 
UK 371 (public) Choice Multiple modes: 
Internet survey and 
To test for framing and mode of administration effects in the 
elicitation of preferences regarding burden of illness 
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Authors (date) Country Sample size 
(type) 
Method a Mode of administration Summary of primary study objective(s) 
non-computer-assisted 
personal interview 
Shah et al. (2014) UK 50 (public) Choice Non-computer-assisted 
personal interview 
To test for support for end-of-life prioritisation 
Shah et al. 
(2015a) 
UK 3,969 (public) DCE Internet survey To test for support for end-of-life prioritisation 
Shiroiwa et al. 
(2010) 
Multiple 5,620 (public) WTP Internet survey To obtain the monetary value of a QALY (in six countries) 
Shiroiwa et al. 
(2013) 
JPN 2,283 (public) WTP Internet survey To obtain the monetary value of a QALY 
Skedgel et al. 
(2015) 
CAN 595 (public); 61 
(decision-
makers) 
DCE Internet survey To test for support for multiple prioritisation criteria 
Stahl et al. (2008) USA 623 (public) Choice Internet survey To test for support for multiple prioritisation criteria 
Stolk et al. (2005) NLD 65 (students, 
researchers, 
health policy 
makers) 
Choice Non-computer-assisted 
personal interview 
To test for support for multiple approaches to priority-setting 
Wouters et al. 
(2017) 
NLD 46 (public, 
individuals with 
experience of 
cancer) 
Q method Multiple modes: Non-
computer-assisted 
personal interview and 
focus group 
Qualitative examination of societal perspectives in relation to 
end-of-life prioritisation 
a Choice = choice exercise that did not include design or analysis methods associated with the DCE technique; DCE = discrete choice experiment; PTO = person trade-off; 1 
WTP = willingness-to-pay 2 
b Made up of 59 data-rich individuals with different types of experiences or expertise in end-of-life in a professional and/or personal capacity (e.g. researchers, 3 
pharmaceutical industry employees, patient group representatives, religious group representatives, clinicians, people with experience of terminal illness in family members), 4 
SOXVWZRµPHWD-UHVSRQGHQWV¶UHSUHVHQWLQJWKHYLHZVRIJHQHUDOSXEOLFUHVSRQGHQWV 5 
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Table 2. Distribution of key variables (n=20) 
Variable Freq. % 
Year of study publication 
- Prior to 2009 
- 2009 onwards 
 
5 
18 
 
21.7% 
78.3% 
Year of study conduct a 
- Prior to 2009 
- 2009 onwards 
 
7 
16 
 
30.4% 
69.6% 
Sample size 
- 1-99 
- 100-999 
- 1,000+ 
 
6 
10 
7 
 
26.1% 
43.5% 
30.4% 
Perspective 
- Own health  
- Social decision-maker  
- Both 
 
2 
19 
2 
 
8.7% 
82.6% 
8.7% 
Method / preference elicitation technique 
- Discrete choice experiment 
- Other choice exercise 
- Analytic hierarchy 
- Budget allocation 
- Q methodology 
- Willingness-to-pay 
- Person trade-off and willingness-to-pay b 
- Ranking exercise and other choice exercise c 
- Other 
 
5 
7 
1 
2 
2 
3 
1 
1 
1 
 
21.7% 
30.4% 
4.3% 
8.7% 
8.7% 
13.0% 
4.3% 
4.3% 
4.3% 
Mode of administration 
- Internet survey 
- Computer-assisted personal interview 
- Non-computer-assisted personal interview 
- Focus group 
- Self-completion paper survey (completed in group setting) 
- Multiple modes d  
 
11 
2 
4 
2 
1 
3 
 
47.8% 
8.7% 
17.4% 
8.7% 
4.3% 
13.0% 
Disease labelled? 
- No 
- Yes ± choice between several named diseases 
- Yes ± choice between treatments for a single named disease or disease area 
 
18 
1 
4 
 
78.3% 
4.3% 
17.4% 
Shortest life expectancy presented 
- 0mths (i.e. imminent death) 
- PWKV/(PWKV 
- PWKV/(PWKV 
- 12mths < LE  
- No length specified 
 
4 
6 
6 
4 
3 
 
17.4% 
26.1% 
26.1% 
17.4% 
13.0% 
Possible to express indifference? 
- Yes 
- No 
- Not reported / unclear 
 
13 
9 
1 
 
56.5% 
39.1% 
4.3% 
Visual aids used? 
- Yes e 
- No  
 
10 
13 
 
43.5% 
56.5% 
Strength of preference examined at the individual respondent level? 
- Yes 
- No 
- Not reported / unclear 
 
12 
10 
1 
 
52.2% 
43.5% 
4.3% 
Qualitative data or explanations for choices sought? 
- Yes 
- No / not reported 
 
9 
14 
 
39.1% 
60.9% 
Impact of background characteristics  
- At least one characteristic found to be associated with preferences 
- No characteristics found to be associated with preferences 
- Not reported 
 
6 
8 
9 
 
26.1% 
34.8% 
39.1% 
Any reference to age-related preferences? 
- Yes 
- No 
 
15 
8 
 
65.2% 
34.8% 
Any reference to time-related preferences? 
- Yes ± an attempt was made to control for or analyse time-related preferences 
- Yes ± time-related preferences were mentioned but not controlled for 
- No 
 
4 
3 
16 
 
17.4% 
13.0% 
69.5% 
Overall finding: end-of-life vs. non-end-of-life   
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Variable Freq. % 
- Consistent with an end-of-life premium 
- Not consistent with an end-of-life premium 
- Mixed or inconclusive evidence 
8 
11 
4 
34.8% 
47.8% 
17.4% 
Overall finding: quality-of-life-improving vs. life-extending end-of-life treatments 
- Quality-of-life improvement preferred 
- Life extension preferred 
- Mixed or inconclusive evidence 
- Not examined / reported 
 
2 
1 
2 
18 
 
8.7% 
4.3% 
8.7% 
78.3% 
a Not always reported ± in some cases this was inferred based on the year of study publication; in other cases 
clarification was sought by means of personal communication with authors 
b Separate methods ± all respondents completed tasks using both methods 
c Hybrid method ± all respondents were asked first to choose which of six patient groups to treat, and then to 
rank the six patient groups in order of preference 
d Internet survey and self-completion paper survey; internet survey and non-computer-assisted personal 
interview; non-computer-assisted personal interview and focus group 
e One study is counted as a study that used visual aids on the basis that visual aids were used in the majority 
of study arms (and for the majority of respondents) 
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Table 3. Distribution of selected variables, by overall study finding 
Variable Evidence consistent with an 
end-of-life premium 
Evidence not consistent with 
an end-of-life premium 
Country 
- UK 
- Europe (non-UK) 
- Rest of the world a 
 
2 
2 
4 
 
5 
3 
3 
Year of study conduct 
- Prior to 2009 
- 2009 onwards 
 
6 
2 
 
8 
3 
Sample size 
- 1-99 
- 100-999 
- 1,000+ 
 
1 
4 
3 
 
3 
4 
4 
Method b 
- DCE 
- Other choice exercise 
- Willingness-to-pay 
- Other 
 
2 
2 
3 
2 
 
2 
4 
1 
4 
Mode of administration c 
- Internet survey 
- Other 
 
5 
3 
 
7 
5 
Shortest life expectancy 
presented 
- PWKV/(PWKV 
- 3mths < LE 
- No length specified 
 
 
5 
3 
1 
 
 
2 
7 
1 
Possible to express 
indifference? 
- Yes 
- No or not reported 
 
 
6 
2 
 
 
5 
6 
Visual aids used? d 
- Yes 
- No or not reported 
 
5 
3 
 
3 
9 
a Includes a multi-country study conducted in Australia, Japan, South Korea, Taiwan, UK and USA. Counted as 
Dµ5HVWRIWKHZRUOG¶VWXG\EHFDXVHWKH8.VDPSOHFRPSULVHGOHVVWKDQRIWKHWRWDOVDPSOH 
b Study combining person trade-off and willingness-to-pay methods counted as two studies since separate 
results are reported for both. Study combining ranking exercise and other choice exercise counted as one study 
since this is considered to be a single hybrid method. 
c Study combining internet survey and non-computer-assisted personal interview modes of administration 
counted as two studies since separate results are reported for both. 
d Study combining visual aid and no visual aid arms counted as two studies since separate results are reported 
for both.      
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Box 1. Final search strategy 
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Figure 1. Flow chart of search results 
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Record Abel 2OVHQ-3ULRULW\SUHIHUHQFHV³HQGRIOLIH´GRHVQRW
matter, but total life does. Value in Health 16, 1063-1066. 
Year of publication 2013 
Year of study conduct 2010 
Country or countries of origin of 
data 
Norway 
Sample size 503 
Type of sample Public 
Sample recruitment process Recruited by agency 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for end of life prioritisation and the fair innings 
approach 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? No 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Remaining lifetime without treatment 
Life expectancy without 
treatment attribute levels 
1yr, 3yrs, 10yrs 
Life expectancy gain from 
treatment attribute levels 
1mth, 3mths, 1yr, 3yrs 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patients to treat 
Was it possible to express 
indifference? 
Yes ± following an initial forced choice without an indifference option, 
respondents were asked to specify how large a gain their less preferred 
patient would need in order for the two patients to have equal priority 
(hence, although respondents were never given an explicit indifference 
option to choose, they were able to express indifference by specifying a 
size of gain for their less preferred patient that was no different from that 
indicated in the initial forced choice question) 
Were visual aids used? No 
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Record Abel 2OVHQ-3ULRULW\SUHIHUHQFHV³HQGRIOLIH´GRHVQRW
matter, but total life does. Value in Health 16, 1063-1066. 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± using benefit trade-off type approach 
Number of tasks completed by 
each respondent 
4 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Evidence of support for the fair innings approach 
Other factors examined Fair innings approach, health gain 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± respondents were asked which factor was most important to them 
when answering the questions 
Was any reference made to 
age-related preferences? 
Yes ± evidence of a desire to reduce inequalities in age at death 
Was any reference made to 
time-related preferences? 
No 
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Record Baker, R., Bateman, I., Donaldson, C., Jones-Lee, M., Lancsar, E., 
Loomes, G., Mason, H., Odejar, M., Pinto Prades, J.L., Robinson, 
A., Ryan, M., Shackley, P., Smith, R., Sugden, R. and Wildman, J., 
2010a. Weighting and valuing quality-adjusted life-years using 
stated preference methods: preliminary results from the Social 
Value of a QALY Project. Health Technology Assessment 14(27). 
Year of publication 2010 
Year of study conduct 2007 
Country or countries of origin of 
data 
UK 
Sample size 587 
Type of sample Public 
Sample recruitment process Recruited by agency 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration CAPI 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? Yes 
Preference elicitation technique Discrete choice experiment 
Perspective Social decision maker 
End of life definition Age at onset and age at death if untreated were included as variables; 
when age at onset = age at death if untreated, the profile describes an 
imminent death scenario where any treatment is life-saving/extending 
Life expectancy without 
treatment attribute levels 
0yrs, 9yrs, 10yrs, various levels > 10yrs (not presented explicitly, but 
can be calculated indirectly by subtracting age at onset from age at death 
if untreated) 
Life expectancy gain from 
treatment attribute levels 
0yrs, 1yr, 5yrs, 10yrs, 20yrs, 40yrs, 60yrs, 79yrs 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No ± when age at onset = age at death if untreated, all treatments are 
necessarily life-extending 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patient groups to treat 
Was it possible to express 
indifference? 
No 
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Record Baker, R., Bateman, I., Donaldson, C., Jones-Lee, M., Lancsar, E., 
Loomes, G., Mason, H., Odejar, M., Pinto Prades, J.L., Robinson, 
A., Ryan, M., Shackley, P., Smith, R., Sugden, R. and Wildman, J., 
2010a. Weighting and valuing quality-adjusted life-years using 
stated preference methods: preliminary results from the Social 
Value of a QALY Project. Health Technology Assessment 14(27). 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
Number of tasks completed by 
each respondent 
8 (+6 tasks using a different method that did not examine end of life, as 
well as attitudinal questions) 
Time taken to complete survey 
reported? 
Yes ± 41 min (average) 
Summary of finding: end of life 
vs. non-end of life 
Mixed or inconclusive evidence 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
In ranking exercise (n=19) conducted in preliminary study, life 
expectancy without treatment was ranked third out of 10 priority-setting 
attributes (below quality of life without treatment but above all patient 
characteristics, e.g. age, lifestyle); age and severity did not have a 
strong impact on choices over and above QALY gains 
Other factors examined Age at onset, age at death, life expectancy gain, quality of life without 
treatment, quality of life gain 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± in preliminary work (but end of life was not a specific topic of 
discussion) 
Was any reference made to 
age-related preferences? 
Yes ± evidence of preference for life-saving treatments for 10 year old 
patients but not for other patients of other ages 
Was any reference made to 
time-related preferences? 
No 
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Record Dolan, P. and Cookson, R., 2000. A qualitative study of the extent 
to which health gain matters when choosing between groups of 
patients. Health Policy, 51, 19-30. 
Year of publication 2000 
Year of study conduct Not reported 
Country or countries of origin of 
data 
UK 
Sample size 60 
Type of sample Public 
Sample recruitment process Random postal invitations 
Criteria for excluding 
respondents and/or 
observations reported? 
No exclusions 
Mode of administration Focus group 
Summary of primary study 
objective(s) 
Qualitative examination of support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker (operationalised using a veil of ignorance condition 
for half of the respondents) 
End of life definition Life expectancy without treatment 
Life expectancy without 
treatment attribute levels 
0yrs, 5yrs, 10yrs, 30yrs (but the sole end of life vs. non-end of life 
question involved a choice between patients with life expectancies of 
10yrs and 30yrs, respectively) 
Life expectancy gain from 
treatment attribute levels 
5yrs, 10yrs, 15yrs, 20yrs (but in the sole end of life vs. non-end of life 
question, life expectancy gain was 10yrs for both candidate recipient 
groups) 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No ± quality of life was examined but in separate questions 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patient groups to treat (with the gain attribute then 
increased/reduced incrementally) 
Was it possible to express 
indifference? 
Yes ± DµVDPHSULRULW\¶RSWLRQZDVDYDLODEOH 
Were visual aids used? No 
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Record Dolan, P. and Cookson, R., 2000. A qualitative study of the extent 
to which health gain matters when choosing between groups of 
patients. Health Policy, 51, 19-30. 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± attribute levels were varied incrementally 
Number of tasks completed by 
each respondent 
6 (+initial discussion and questionnaire on health care priority-setting in 
general) 
Time taken to complete survey 
reported? 
Yes ± meeting lasted for two hours 
Summary of finding: end of life 
vs. non-end of life 
Mixed or inconclusive evidence 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Veil of ignorance perspective (vs. social decision maker) had no 
discernible impact; authors conclude from data that "equality of access 
should prevail over the maximisation of benefits" (p.19) 
Other factors examined Quality of life without treatment, quality of life with treatment; other 
factors were mentioned by respondents but these were either irrelevant 
or factors that they were not supposed to have considered (e.g. costs) 
Impact of background 
characteristics reported? 
Yes ± none found to influence propensity to favour treating end of life 
patients 
Were qualitative data or 
explanatory factors sought? 
Yes ± study was predominantly a qualitative exercise 
Was any reference made to 
age-related preferences? 
Yes ± but age was intended to be an irrelevant factor 
Was any reference made to 
time-related preferences? 
No 
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Record Dolan, P. and Shaw, R., 2004. A note on a discussion group study 
of public preferences regarding priorities in the allocation of 
donor kidneys. Health Policy, 68, 31-36. 
Year of publication 2004 
Year of study conduct Not reported 
Country or countries of origin of 
data 
UK 
Sample size 23 
Type of sample Public  
Sample recruitment process Recruited by agency 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Focus group 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Life expectancy without transplant 
Life expectancy without 
treatment attribute levels 
1yr, 4yrs, 7yrs, 10yrs, 13yrs, 16yrs 
Life expectancy gain from 
treatment attribute levels 
5yrs, 10yrs, 15yrs, 20yrs, 25yrs, 30yrs 
Was disease labelled or named? Yes ± kidney failure 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of six patients should receive a kidney transplant 
Was it possible to express 
indifference? 
No 
Were visual aids used? No 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Dolan, P. and Shaw, R., 2004. A note on a discussion group study 
of public preferences regarding priorities in the allocation of 
donor kidneys. Health Policy, 68, 31-36. 
Number of tasks completed by 
each respondent 
3 
Time taken to complete survey 
reported? 
Yes ± two meetings, each of which lasted for two hours 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Benefit from transplantation was the most important criterion overall; 
some participants chose to prioritise those with dependants 
Other factors examined Other factors mentioned by participants: age, family responsibilities, 
waiting time, cause, whether a re-transplantation or not 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± study was predominantly a qualitative exercise 
Was any reference made to 
age-related preferences? 
Yes ± the participants who had chosen to treat the patient with shortest 
life expectancy without transplant did not continue to do so when it was 
revealed that this patient was the oldest of the six candidate recipients 
Was any reference made to 
time-related preferences? 
No 
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Record Dolan, P. and Tsuchiya, A., 2005. Health priorities and public 
preferences: the relative importance of past health experience 
and future health prospects. Journal of Health Economics, 24, 
703-714. 
Year of publication 2005 
Year of study conduct 2002 
Country or countries of origin of 
data 
UK 
Sample size 100 
Type of sample Public 
Sample recruitment process Postal invitation 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded respondents who did not complete all of the tasks 
Mode of administration Self-completion paper survey (administered in group setting) 
Summary of primary study 
objective(s) 
To compare support for prioritisation according to age vs. prioritisation 
according to severity/life expectancy 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? No 
Preference elicitation technique Ranking exercise and other choice exercise 
Perspective Social decision maker  
End of life definition Future years without treatment 
Life expectancy without 
treatment attribute levels 
1yr, 6yrs 
Life expectancy gain from 
treatment attribute levels 
3yrs  
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No ± a question examining quality of life improvement was included, but 
the size of the life extension was fixed 
What were respondents 
choosing between (or choosing 
to do)? 
Which of six patient groups to treat; then to rank the six patient groups 
Was it possible to express 
indifference? 
No  
Were visual aids used? No 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Dolan, P. and Tsuchiya, A., 2005. Health priorities and public 
preferences: the relative importance of past health experience 
and future health prospects. Journal of Health Economics, 24, 
703-714. 
Number of tasks completed by 
each respondent 
4 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Future health (quality of life without treatment) did not have a 
statistically significant effect on choices made, whereas past years (age) 
had a strong effect 
Other factors examined Past age, past health, quality of life without treatment  
Impact of background 
characteristics reported? 
Yes ± age, education and employment status were all found to have 
statistically significant interactions with life expectancy without treatment  
Were qualitative data or 
explanatory factors sought? 
No ± discussions were not recorded as it was not intended to be a 
qualitative study 
Was any reference made to 
age-related preferences? 
Yes ± younger patient groups were always chosen over older ones 
Was any reference made to 
time-related preferences? 
No 
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Record Lim, M.K., Bae, E.Y., Choi, S.E., Lee, E.K. and Lee, T.J., 2012. 
Eliciting public preference for health-care resource allocation in 
South Korea. Value in Health, 15, S91-S94. 
Year of publication 2012 
Year of study conduct 2010 
Country or countries of origin of 
data 
Korea 
Sample size 800 
Type of sample Public 
Sample recruitment process Recruited by agency 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded multiple responses from the same IP address 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No (but focus groups were conducted, in part to inform the selection of 
attributes in the internet survey) 
Preference elicitation technique Discrete choice experiment 
Perspective Social decision maker 
End of life definition Life expectancy without treatment 
Life expectancy without 
treatment attribute levels 
1yr, 5yrs, 10yrs, 20yrs, 25yrs, 35yrs 
Life expectancy gain from 
treatment attribute levels 
0yrs, 1yr, 5yrs, 10yrs, 20yrs, 30yrs 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No  
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patients to treat 
Was it possible to express 
indifference? 
Not reported 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Lim, M.K., Bae, E.Y., Choi, S.E., Lee, E.K. and Lee, T.J., 2012. 
Eliciting public preference for health-care resource allocation in 
South Korea. Value in Health, 15, S91-S94. 
Number of tasks completed by 
each respondent 
17 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
All attributes had statistically significant coefficients with signs that were 
consistent with the authors' expectations (QALY gain ± positive; quality 
of life before treatment ± negative; patient's household income ± 
negative) 
Other factors examined QALY gain; quality of life before treatment; household income group 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± using focus groups (but end of life was not a specific topic for 
discussion) 
Was any reference made to 
age-related preferences? 
No 
Was any reference made to 
time-related preferences? 
No 
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Record Linley, W.G. and Hughes, D.A., 2013. Societal views on NICE, 
Cancer drugs fund and value-based pricing criteria for prioritising 
medicines: a cross-sectional survey of 4118 adults in Great 
Britain. Health Economics, 22, 948-964. 
Year of publication 2013 
Year of study conduct 2011 
Country or countries of origin of 
data 
UK 
Sample size 4,118 
Type of sample Public 
Sample recruitment process Recruited by agency 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No ± end of life was one of many prioritisation criteria examined 
Pilot reported? Yes 
Preference elicitation technique Budget allocation 
Perspective Social decision maker 
End of life definition Fatal disease that leads to death in 18 months without treatment 
Life expectancy without 
treatment attribute levels 
18mths, 60mths 
Life expectancy gain from 
treatment attribute levels 
3mths, 6mths 
Was disease labelled or named? No EXWSUHIHUHQFHVUHJDUGLQJµIDWDOFDQFHU¶ZHUHH[DPLQHGLQDVHSDUDWH
question) 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
To allocate a fixed budget between two groups of patients 
Was it possible to express 
indifference? 
Yes ± a 50:50 split option was available 
Were visual aids used? No 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± respondents could choose from 11 different distributions of 
IXQGLQJDQGIXUWKHUµKHDOWKJDLQWUDGH-RII¶DQGµFRVWWUDGH-RII¶
approaches were also used 
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Record Linley, W.G. and Hughes, D.A., 2013. Societal views on NICE, 
Cancer drugs fund and value-based pricing criteria for prioritising 
medicines: a cross-sectional survey of 4118 adults in Great 
Britain. Health Economics, 22, 948-964. 
Number of tasks completed by 
each respondent 
18 (of which two examined end of life explicitly) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Evidence of support for prioritising treatment of severe illness, but not for 
prioritising treatment of cancer specifically 
Other factors examined Health gain; many others examined separately from end of life 
Impact of background 
characteristics reported? 
Yes ± none found to influence propensity to favour treating end of life 
patients 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
Yes ± respondents did not support giving priority to the treatment of 
children overall (questions about children were separate from those 
about end of life) 
Was any reference made to 
time-related preferences? 
No 
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Record McHugh, N., Baker, R.M., Mason, H., Williamson, L., van Exec, J., 
Deogaonkar, R., Collins, M. and Donaldson, C., 2015. Extending 
life for people with a terminal illness: a moral right and an 
expensive death? Exploring societal perspectives. BMC Medical 
Ethics, 16(14). 
Year of publication 2015 
Year of study conduct Not reported 
Country or countries of origin of 
data 
UK 
Sample size 61  
Type of sample Individuals with different types of experiences or expertise in end of life 
in a professional or personal capacity (e.g. researchers, clinicians, people 
with experience of terminal illness) 
Sample recruitment process Purposive (to identify data-rich respondents) 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Non-computer-assisted personal interview 
Summary of primary study 
objective(s) 
Qualitative examination of societal perspectives in relation to end of life 
prioritisation 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? Yes 
Preference elicitation technique Q methodology (technique that combines card sort and ranking exercise) 
Perspective Social decision maker (though a minority of statements were framed 
using an own health perspective) 
End of life definition Described in multiple ways HJµWHUPLQDOO\LOO¶µGLHVRRQ¶ 
Life expectancy without 
treatment attribute levels 
N/A 
Life expectancy gain from 
treatment attribute levels 
N/A 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
Yes 
What were respondents 
choosing between (or choosing 
to do)? 
Rank statements according to how much they agreed or disagreed with 
them   
Was it possible to express 
indifference? 
Yes ± in the grid ranging from -5 (most disagree) to +5 (most agree), 
respondents were able to place statements in the position marked 0 
Were visual aids used? No 
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Record McHugh, N., Baker, R.M., Mason, H., Williamson, L., van Exec, J., 
Deogaonkar, R., Collins, M. and Donaldson, C., 2015. Extending 
life for people with a terminal illness: a moral right and an 
expensive death? Exploring societal perspectives. BMC Medical 
Ethics, 16(14). 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± strength of preference indicated by position in which statements 
were placed on the grid 
Number of tasks completed by 
each respondent 
1 (comprising sorting and placing of 49 statements on grid) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Mixed or inconclusive evidence 
Summary of finding: quality of 
life improvement vs. life 
extension 
Mixed or inconclusive evidence 
Other results of potential 
interest 
Three shared accounts identified: (1) A population perspective ± value for 
money, no special cases; (2) Life is precious ± valuing life-extensions and 
patient choice; (3) Valuing wider benefits and opportunity cost ± the 
quality of life and death 
Other factors examined Alternative perspectives and approaches to resource allocation ± e.g. 
health-maximisation, provision of treatments to patients with non-
terminal conditions 
Impact of background 
characteristics reported? 
Yes (though authors warn about making generalisations based on 
qualitative samples) ± e.g. no academics helped to define the shared 
account most closely related to an end of life premium  
Were qualitative data or 
explanatory factors sought? 
Yes ± study was in part a qualitative exercise 
Was any reference made to 
age-related preferences? 
Yes ± e.g. one statement was ZRUGHG³,WKLQNOLIH-extending treatments 
IRUSHRSOHZKRDUHWHUPLQDOO\LOODUHRIOHVVYDOXHDVSHRSOHJHWROGHU´ 
Was any reference made to 
time-related preferences? 
No reference to time discounting per se, but several statements referred 
to the value of time ± HJ³It is important to give a dying person and 
their family time to prepare for their death, put their affairs in order, 
make peace and say goodbyes´ 
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Record Pennington, M., Baker, R., Brouwer, W., Mason, H., Hansen, D. G., 
Robinson, A. and Donaldson, C., 2015. Comparing WTP values of 
different types of QALY gain elicited from the general public. 
Health Economics, 24, 280-293. 
Year of publication 2015 
Year of study conduct 2009-2010 
Country or countries of origin of 
data 
Denmark, France, Hungary, Netherlands, Norway, Poland, Spain, 
Sweden, UK 
Sample size 17,657 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded protest responders; respondents who expected to live for 
less than 6yrs were directed to a different questionnaire (not reported); 
impact of other exclusions reported in sensitivity analysis 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To compare willingness to pay for different types of QALY gain 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? Yes 
Preference elicitation technique Willingness to pay 
Perspective Own health 
End of life definition "Imminent, premature death from a life threatening disease" (at least six 
years before respondent's self-reported expected end of life 
Life expectancy without 
treatment attribute levels 
Imminent (as above), UHVSRQGHQW¶VVHOI-reported life expectancy 
Life expectancy gain from 
treatment attribute levels 
1 QALY worth of life extension (at a quality of life level consistent with 
UHVSRQGHQW¶VVHOI-reported health) 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No ± quality of life was examined but in separate questions 
What were respondents 
choosing between (or choosing 
to do)? 
What the maximum amount they would be willing to pay for a given 
specific gain 
Was it possible to express 
indifference? 
Yes ± respondents could provide the same willingness to pay value for 
multiple gains 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± strength of preference indicated by differing willingness to pay 
amounts 
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Record Pennington, M., Baker, R., Brouwer, W., Mason, H., Hansen, D. G., 
Robinson, A. and Donaldson, C., 2015. Comparing WTP values of 
different types of QALY gain elicited from the general public. 
Health Economics, 24, 280-293. 
Number of tasks completed by 
each respondent 
5 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
When comparing QALY gains obtained in the near future, life extensions 
were valued more highly then quality of life improvements; low median 
values for OLIHH[WHQVLRQVDWUHVSRQGHQWV¶H[SHFWHGHQGRIOLIH strongly 
influenced by the large number of observations at zero 
Other factors examined Avoiding quality of life loss now (over 4yrs or 10yrs); avoiding time spent 
in coma (intended to elicit a gain in longevity occurring in the near 
future) 
Impact of background 
characteristics reported? 
Yes ± older age and poorer health associated with lower willingness to 
pay values for life extension in imminent death scenario 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
Yes ± K\SRWKHWLFDOVFHQDULRVZDVEDVHGRQUHVSRQGHQWV¶DFWXDODJHVDQG
self-reported life expectancies 
Was any reference made to 
time-related preferences? 
Yes ± authors acknowledge that gains in the future would be discounted, 
and that for an individual facing immediate death the normal opportunity 
cost considerations may not apply 
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Record Pinto-Prades, J.L., Sanchez-Martínez, F.I., Corbacho, B., Baker, R., 
2014. Valuing QALYs at the end of Life. Social Science and 
Medicine, 113, 5-14. 
Year of publication 2014 
Year of study conduct 2010 
Country or countries of origin of 
data 
Spain 
Sample size 813 
Type of sample Public 
Sample recruitment process Door-knock 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded protest responders in the willingness to pay tasks 
Mode of administration Computer-assisted personal interview 
Summary of primary study 
objective(s) 
To test for support for end of life prioritisation 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? Yes 
Preference elicitation technique Willingness to pay and person trade-off 
Perspective Both ± own health (willingness to pay tasks); social decision maker 
(person trade-off tasks) 
End of life definition Life expectancy without treatment 
Life expectancy without 
treatment attribute levels 
3mths, 6mths, 18mths 
Life expectancy gain from 
treatment attribute levels 
6mths, 18mths  
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
Yes 
What were respondents 
choosing between (or choosing 
to do)? 
What the maximum amount they would be willing to pay for a 10% 
chance of improving their condition in a specified way (willingness to pay 
tasks); the number of patients treated of one type they consider 
equivalent to treating one patient of another type (person trade-off 
tasks) 
Was it possible to express 
indifference? 
Yes ± respondents could provide the same willingness to pay value for 
multiple gains or choose an equal number of both types of patient in the 
person trade-off task 
Were visual aids used? Yes 
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Record Pinto-Prades, J.L., Sanchez-Martínez, F.I., Corbacho, B., Baker, R., 
2014. Valuing QALYs at the end of Life. Social Science and 
Medicine, 113, 5-14. 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± strength of preference indicated by differing willingness to pay 
amounts and levels of trade-off 
Number of tasks completed by 
each respondent 
6 
Time taken to complete survey 
reported? 
Yes ± 21 minutes on average 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Quality of life improvement preferred 
Other results of potential 
interest 
Reasonably large proportion of respondents did not give too much value 
to a short life extension but those who did were willing to pay quite a lot 
(similar split of opinion observed in PTO responses) 
Other factors examined None 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
No 
Was any reference made to 
time-related preferences? 
No 
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Record Richardson, J., Sinha, K., Iezzi, A. and Maxwell, A., 2012. 
Maximising health versus sharing: Measuring preferences for the 
allocation of the health budget. Social Science & Medicine, 75, 
1351-1361. 
Year of publication 2012 
Year of study conduct 2009-2010 
Country or countries of origin of 
data 
Australia 
Sample size 544 
Type of sample Public 
Sample recruitment process Internet panel; targeted postal invitations (based on socioeconomic 
characteristics of residential postcodes) 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded respondents whose comments or answers indicated 
misunderstanding 
Mode of administration Multiple modes: internet survey; self-completion paper survey (postal) 
Summary of primary study 
objective(s) 
To test a technique for measuring support for health-maximisation and 
health sharing 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No 
Preference elicitation technique Novel cross between a discrete choice and budget allocation exercise 
Perspective Social decision maker 
End of life definition Immediate death without treatment 
Life expectancy without 
treatment attribute levels 
Multiples of 4yrs and 6yrs 
Life expectancy gain from 
treatment attribute levels 
4yrs, 6yrs, 8yrs, 12yrs 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of four patients to give a life extension to 
Was it possible to express 
indifference? 
No 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
Not reported / unclear 
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Record Richardson, J., Sinha, K., Iezzi, A. and Maxwell, A., 2012. 
Maximising health versus sharing: Measuring preferences for the 
allocation of the health budget. Social Science & Medicine, 75, 
1351-1361. 
Number of tasks completed by 
each respondent 
1 (comprising 18 to 29 iterations) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Mixed or inconclusive evidence 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Results indicate that respondents were primarily concerned with outcome 
egalitarianism (as opposed to maximising health outcomes) 
Other factors examined Sharing / outcome egalitarianism 
Impact of background 
characteristics reported? 
Yes ± none found to influence propensity to favour treating end of life 
patients 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
No ± but all patients start at the same age (25yrs), so the results could 
be interpreted in terms of desire to equalise expected age at death 
Was any reference made to 
time-related preferences? 
Yes ± authors acknowledge that there may be some variation from the 
orthodox economic prediction if time discounting is taken into account 
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Record Rowen, D., Brazier, J., Mukuria, C., Keetharuth, A, Risa Hole, A., 
Tsuchiya, A., Whyte, S. and Shackley, P., 2016a. Eliciting societal 
preferences for weighting QALYs for burden of illness and end of 
life. Medical Decision Making, 36, 210-222. 
Year of publication 2015 
Year of study conduct Not reported 
Country or countries of origin of 
data 
UK 
Sample size 3,669 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
No exclusions  
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? Yes 
Preference elicitation technique Discrete choice experiment 
Perspective Social decision maker 
End of life definition Life expectancy without treatment; dummy variable in the modelling 
representing the cut-offs associated with the NICE criteria 
Life expectancy without 
treatment attribute levels 
3mths, 6mths, 9mths, 1yr, 2yrs, 5yrs, 10yrs, 30yrs, 60yrs 
Life expectancy gain from 
treatment attribute levels 
0mths, 1mth, 3mths, 6mths, 9mths, 1yr, 3yrs, 10yrs, 60yrs 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patient groups to treat 
Was it possible to express 
indifference? 
No 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Rowen, D., Brazier, J., Mukuria, C., Keetharuth, A, Risa Hole, A., 
Tsuchiya, A., Whyte, S. and Shackley, P., 2016a. Eliciting societal 
preferences for weighting QALYs for burden of illness and end of 
life. Medical Decision Making, 36, 210-222. 
Number of tasks completed by 
each respondent 
10 (+further attitudinal questions) 
Time taken to complete survey 
reported? 
Yes ± 21 minutes on average 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Preference for larger QALY gains, but at a diminishing rate; some support 
for prioritising those with higher burden of illness, though not robust 
Other factors examined QALY gain, burden of illness 
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± in piloting and via attitudinal questions 
Was any reference made to 
age-related preferences? 
No ± age attribute was purposely omitted 
Was any reference made to 
time-related preferences? 
No 
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Record Rowen, D., Brazier, J., Keetharuth, A., Tsuchiya, A. and Mukuria, 
C., 2016b. Comparison of modes of administration and alternative 
formats for eliciting societal preferences for burden of illness. 
Applied Health Economics and Health Policy, 14, 89-104. 
Year of publication 2016 
Year of study conduct Not reported 
Country or countries of origin of 
data 
UK 
Sample size 371 
Type of sample Public 
Sample recruitment process Door-knock; internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
No exclusions 
Mode of administration Multiple modes: non-computer-assisted personal interview (except in 
some arms where the introductory video was shown on a computer); 
internet survey 
Summary of primary study 
objective(s) 
To test for framing and mode of administration effects in the elicitation of 
preferences regarding burden of illness a 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Life expectancy without treatment / due to condition 
Life expectancy without 
treatment attribute levels 
5yrs, 10yrs, 15yrs (but the sole end of life vs. non-end of life question 
involved a choice between patients with life expectancies of 5yrs and 
10yrs, respectively) 
Life expectancy gain from 
treatment attribute levels 
0yrs, 1yr, 2yrs (but in the sole end of life vs. non-end of life question, life 
expectancy gain was 1yr for both candidate recipient groups) 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
Yes 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patient groups to treat 
Was it possible to express 
indifference? 
No 
Were visual aids used? Yes (in four of six arms; n=240); no (in two of six arms; n=131) 
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Record Rowen, D., Brazier, J., Keetharuth, A., Tsuchiya, A. and Mukuria, 
C., 2016b. Comparison of modes of administration and alternative 
formats for eliciting societal preferences for burden of illness. 
Applied Health Economics and Health Policy, 14, 89-104. 
Strength of preference 
examined at the individual 
respondent level? 
No 
Number of tasks completed by 
each respondent 
9 (2 of which were practice tasks, but were reported in full by authors) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported (two questions involved choices between quality 
of life improvements and life extensions, but life expectancy without 
treatment was set to 10/15 years so is deemed not to describe an end of 
life context)  
Other results of potential 
interest 
Responses were affected by mode of administration but not by question 
wording or use of visual aids   
Other factors examined QALY gain (size and type); burden of illness 
Impact of background 
characteristics reported? 
No ± not for question of relevance to end of life (for other questions, few 
sociodemographic variables were significant) 
Were qualitative data or 
explanatory factors sought? 
No ± follow-up questions were asked but these focused on framing issues 
and task understanding rather than on reasons for choices 
Was any reference made to 
age-related preferences? 
No 
Was any reference made to 
time-related preferences? 
No 
 
a The only task in this study relevant to the research question underpinning the literature review was labelled 
DVDµSUDFWLFHTXHVWLRQ¶+RZHYHULQWKHSDSHUWKHDXWKRUVGRQRWWUHDWWKHSUDFWLFHTXHVWLRQDVDQ\OHVVYDOLG
or reliable than the main (non-practice) questions, and present a full analysis of the responses to the practice 
questions. A notable feature of the practice questions in this study was that respondents were, in effect, asked 
to reconsider and confirm their responses. This suggests that the responses should not be interpreted as 
constituting lower quality data than the responses to the main questions. The decision to include this study in 
the review was informed by a discussion with one of the study authors (Tsuchiya, A., personal communication, 
20 Sep 201
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Record Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2014. Valuing health at 
the end of life: an empirical study of public preferences. European 
Journal of Health Economics, 15, 389-399. 
Year of publication 2014 
Year of study conduct 2011 
Country or countries of origin of 
data 
UK 
Sample size 50 
Type of sample Public 
Sample recruitment process Door-knock 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Non-computer-assisted personal interview 
Summary of primary study 
objective(s) 
To test for support for end of life prioritisation 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? Yes 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Life expectancy without treatment 
Life expectancy without 
treatment attribute levels 
1yr, 10yrs 
Life expectancy gain from 
treatment attribute levels 
6mths, 1yr 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
Yes 
What were respondents 
choosing between (or choosing 
to do)? 
Which patient to treat 
Was it possible to express 
indifference? 
Yes ± DQµ,KDYHQRSUHIHUHQFH¶RSWLRQZDVDYDLODEOH 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2014. Valuing health at 
the end of life: an empirical study of public preferences. European 
Journal of Health Economics, 15, 389-399. 
Number of tasks completed by 
each respondent 
6 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Quality of life improvement preferred 
Other results of potential 
interest 
No evidence that age- or time-related preferences are motivating factors 
for choosing to treat end of life patient; no evidence that concern about 
the life stage of end of life patients is a motivating factor for preferring 
either life-extending or quality of life-improving treatments for those 
patients 
Other factors examined Age, time preference  
Impact of background 
characteristics reported? 
No 
Were qualitative data or 
explanatory factors sought? 
Yes ± respondents indicated the reasons for their choices by choosing 
from a list 
Was any reference made to 
age-related preferences? 
Yes ± no evidence that concern about age is a motivating factor for 
choosing to treat end of life patient 
Was any reference made to 
time-related preferences? 
Yes ± one task involved choosing between a patient who had known their 
prognosis for some time and another who had only just learned their 
prognosis (life expectancy without treatment was the same for both) 
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Record Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2015a. Valuing health at 
the end of life: a stated preference discrete choice experiment. 
Social Science & Medicine 124, 48-56. 
Year of publication 2015 
Year of study conduct 2011 
Country or countries of origin of 
data 
UK 
Sample size 3,969 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± excluded respondents who spent insufficient time completing the 
survey 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for end of life prioritisation 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes 
Pilot reported? Yes 
Preference elicitation technique Discrete choice experiment 
Perspective Social decision maker 
End of life definition Life expectancy without treatment; dummy variable in the modelling 
representing the cut-offs associated with the NICE criteria 
Life expectancy without 
treatment attribute levels 
3mths, 12mths, 24mths, 36mths, 60mths 
Life expectancy gain from 
treatment attribute levels 
0mths, 1mth, 2mths, 3mths, 6mths, 12mths 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
Yes 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patients to treat 
Was it possible to express 
indifference? 
No 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Shah, K.K., Tsuchiya, A. and Wailoo, A.J., 2015a. Valuing health at 
the end of life: a stated preference discrete choice experiment. 
Social Science & Medicine 124, 48-56. 
Number of tasks completed by 
each respondent 
10 (+2 further tasks examining the issue of preparedness) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Life extension preferred 
Other results of potential 
interest 
Majority of respondents supported a mixture of the QALY-maximisation 
and priority-to-worst-off approaches to priority-setting 
Other factors examined Quality of life without treatment, preparedness 
Impact of background 
characteristics reported? 
Yes ± no characteristics found to be associated with preferences 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
No ± age attribute was purposely omitted 
Was any reference made to 
time-related preferences? 
µ7LPHZLWKNQRZOHGJH¶DWWULEXWHZDVH[DPLQHGEXWWKHUHVXOWVZHUHQRW
reported; authors note that applying a positive discount rate would likely 
further strengthen their finding of a lack of support for an end of life 
premium 
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Record Shiroiwa, T., Igarashi, A., Fukuda, T. and Ikeda, S., 2013. WTP for 
a QALY and health states: More money for severer health states? 
Cost Effectiveness and Resource Allocation, 11(22). 
Year of publication 2013 
Year of study conduct 2011 
Country or countries of origin of 
data 
Japan 
Sample size 2,283 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± recruited respondents aged 20 to 69 years only (thereby excluding 
individuals aged 70 years and older) 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To obtain the monetary value of a QALY 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? No 
Preference elicitation technique Willingness to pay 
Perspective Own health 
End of life definition Life expectancy without treatment (end of life scenario 1); life-
threatening situation (end of life scenario 2) 
Life expectancy without 
treatment attribute levels 
1mth 
Life expectancy gain from 
treatment attribute levels 
2mths, 4mths, 7mths, 14mths 
Was disease labelled or named? No 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No ± questions examining quality of life improvement were included, but 
these were related to non-end of life scenarios 
What were respondents 
choosing between (or choosing 
to do)? 
Whether or not to pay set amounts for a given specific gain 
Was it possible to express 
indifference? 
Yes ± respondents could provide the same willingness to pay value for 
multiple gains 
Were visual aids used? No 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± strength of preference indicated by differing willingness to pay 
amounts 
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Record Shiroiwa, T., Igarashi, A., Fukuda, T. and Ikeda, S., 2013. WTP for 
a QALY and health states: More money for severer health states? 
Cost Effectiveness and Resource Allocation, 11(22). 
Number of tasks completed by 
each respondent 
1 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Monetary value of a QALY is higher for severe health states than for mild 
health states 
Other factors examined Avoiding quality of life loss now (for periods lasting between 4 and 20 
months) 
Impact of background 
characteristics reported? 
No ± not specifically for questions of relevance to end of life (overall, 
willingness to pay values were significantly correlated with household 
income) 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
No 
Was any reference made to 
time-related preferences? 
No 
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Record Shiroiwa, T., Sung, Y.K., Fukuda, T., Lang, H.C., Bae, S.C. and 
Tsutani, K., 2010. International survey on willingness-to-pay 
(WTP) for one additional QALY gained: what is the threshold of 
cost effectiveness? Health Economics, 19, 422-437. 
Year of publication 2010 
Year of study conduct 2007-2008 
Country or countries of origin of 
data 
Australia, Japan, Korea, Taiwan, UK, US 
Sample size 5,620 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
Yes ± recruited respondents aged 20 to 59 years only (thereby excluding 
individuals aged 60 years and older) 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To obtain the monetary value of a QALY (in six countries) 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? Yes 
Preference elicitation technique Willingness to pay 
Perspective Both ± own health (end of life and non-end of life scenarios); social 
decision maker (end of life scenario only) 
End of life definition Serious illness that immediately threatens [your / their] life 
Life expectancy without 
treatment attribute levels 
0yrs, 5yrs 
Life expectancy gain from 
treatment attribute levels 
1yr 
Was disease labelled or named? No (but disease was described as a life-limiting illness such as metastatic 
cancer) 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Whether or not to pay set amounts for a given life extension  
Was it possible to express 
indifference? 
Yes ± respondents could provide the same willingness to pay value for 
multiple gains 
Were visual aids used? No 
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Record Shiroiwa, T., Sung, Y.K., Fukuda, T., Lang, H.C., Bae, S.C. and 
Tsutani, K., 2010. International survey on willingness-to-pay 
(WTP) for one additional QALY gained: what is the threshold of 
cost effectiveness? Health Economics, 19, 422-437. 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± strength of preference indicated by differing willingness to pay 
amounts 
Number of tasks completed by 
each respondent 
4 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
In Japan and Korea, the highest willingness to pay values observed were 
for a life extension for a family member; in Australia, UK and US, the 
highest willingness to pay values observed were for a life extension for 
an unidentified member of society  
Other factors examined Willingness to pay for a life extension for a family member and for an 
unidentified member of society facing life-threatening illness  
Impact of background 
characteristics reported? 
Yes ± respondents with high household income and education levels gave 
higher willingness to pay values for life extensions at the end of life 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
No 
Was any reference made to 
time-related preferences? 
Yes ± authors interpret difference between willingness to pay values in 
end of life and non-end of life scenarios in terms of time preference, and 
use the data to estimate discount rates for each country (ranging from 
1.6% to 6.8%) 
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Record Skedgel, C., Wailoo, A. and Akehurst, R., 2014. Societal 
preferences for distributive justice in the allocation of health care 
resources: a latent class discrete choice experiment. Medical 
Decision Making, 35, 94-105. 
Year of publication 2015 
Year of study conduct 2011-2012 
Country or countries of origin of 
data 
Canada 
Sample size 656 
Type of sample Public, decision-makers 
Sample recruitment process Internet panel (public); flyers and email invitations (decision-makers) 
Criteria for excluding 
respondents and/or 
observations reported? 
No exclusions 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? Yes 
Preference elicitation technique Discrete choice experiment 
Perspective Social decision maker 
End of life definition Life expectancy without treatment 
Life expectancy without 
treatment attribute levels 
1mth, 5yrs, 10yrs 
Life expectancy gain from 
treatment attribute levels 
1yr, 5yrs, 10yrs 
Was disease labelled or named? Yes ± cancer  
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two health programmes to allocate (all of) a fixed budget to 
Was it possible to express 
indifference? 
No 
Were visual aids used? Yes 
Strength of preference 
examined at the individual 
respondent level? 
No 
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Record Skedgel, C., Wailoo, A. and Akehurst, R., 2014. Societal 
preferences for distributive justice in the allocation of health care 
resources: a latent class discrete choice experiment. Medical 
Decision Making, 35, 94-105. 
Number of tasks completed by 
each respondent 
11 
Time taken to complete survey 
reported? 
Yes ± 9.5 minutes on average (public) 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Evidence of support for treating younger and larger patient groups; and 
for deprioritising treatment for those who will be in poor health after 
treatment 
Other factors examined Age, quality of life without treatment, quality of life with treatment, 
number of patients treated 
Impact of background 
characteristics reported? 
Yes ± background characteristics were not statistically significantly 
associated with (latent) class membership 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
Yes ± evidence of support for treating younger patients, though the 
author did not interact the age and life expectancy without treatment 
variables 
Was any reference made to 
time-related preferences? 
No 
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Record Stahl, J.E., Tramontano, A.C., Swan, J.S. and Cohen, B.J., 2008. 
Balancing urgency, age and quality of life in organ allocation 
decisions²what would you do?: a survey. Journal of Medical 
Ethics, 34, 109-115. 
Year of publication 2008 
Year of study conduct Not reported 
Country or countries of origin of 
data 
USA 
Sample size 623 
Type of sample Public 
Sample recruitment process Internet panel 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Internet survey 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
Yes  
Pilot reported? No 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Urgency (life expectancy without treatment) 
Life expectancy without 
treatment attribute levels 
Levels not reported explicitly, but appear to cover: <1mth, 3mths, 
6mths, 9mths, 12mths, 15mths, 18mths, 21mths, 24mths 
Life expectancy gain from 
treatment attribute levels 
1yr, 2yrs, 3yrs, 4yrs, 5yrs, 6yrs, 7yrs, 8yrs, 9yrs, 10yrs 
Was disease labelled or named? Yes ± organ transplantation 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patients to give an organ transplant to 
Was it possible to express 
indifference? 
Yes ± DµFDQ¶WGHFLGH¶RSWLRQZDVDYDLODEOH 
Were visual aids used? No 
Strength of preference 
examined at the individual 
respondent level? 
Yes ± attribute levels were varied incrementally 
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Record Stahl, J.E., Tramontano, A.C., Swan, J.S. and Cohen, B.J., 2008. 
Balancing urgency, age and quality of life in organ allocation 
decisions²what would you do?: a survey. Journal of Medical 
Ethics, 34, 109-115. 
Number of tasks completed by 
each respondent 
33 (unclear whether each respondent answered all or a subset of the 33) 
Time taken to complete survey 
reported? 
No 
Summary of finding: end of life 
vs. non-end of life 
Evidence consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
When both patients have better (worse) than average quality of life, 
respondents preferred to treat the worse-off (better-off) patient 
Other factors examined Age, life expectancy with treatment, quality of life without treatment, 
quality of life with treatment; single-factor and cross-factor trade-offs 
examined 
Impact of background 
characteristics reported? 
Yes ± older (>40yrs) and female respondents had narrower windows of 
indifference ± i.e. preferred to treat end of life patient until the difference 
between the life expectancies of the patients was extremely small; 
respondents with transplant recipient in family placed greater importance 
on quality of life without treatment then life expectancy without 
treatment unless the latter was extremely short (<1mth) 
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
Yes ± for an older patient to receive priority over a younger patient, the 
older patient must be at least 2.5mths closer to their end of life than the 
younger patient 
Was any reference made to 
time-related preferences? 
No 
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Record Stolk, E.A., Pickee, S.J., Ament, A.H. and Busschbach, J.J., 2005. 
Equity in health care prioritisation: an empirical inquiry into 
social value. Health Policy, 74(3), 343-355. 
Year of publication 2005 
Year of study conduct Not reported 
Country or countries of origin of 
data 
Netherlands 
Sample size 65 
Type of sample Students, researchers, health policy makers 
Sample recruitment process Not reported 
Criteria for excluding 
respondents and/or 
observations reported? 
No 
Mode of administration Non-computer-assisted personal interview 
Summary of primary study 
objective(s) 
To test for support for multiple prioritisation criteria 
Was end of life (or a related 
term) mentioned explicitly in 
the study objectives? 
No 
Pilot reported? Yes 
Preference elicitation technique Other choice exercise 
Perspective Social decision maker 
End of life definition Information on life expectancy without treatment not provided explicitly 
but could be calculated given information on age, life expectancy 
(disease-free and with disease) and life years lost due to disease 
Life expectancy without 
treatment attribute levels 
0.5yrs, 2.25yrs, 3yrs, 11yrs, 14yrs, 14.5yrs, 16yrs, 20yrs, 20.5yrs, 
22.5yrs 
Life expectancy gain from 
treatment attribute levels 
N/A ± treated patient would be given a µwonder pill¶ which would relieve 
them of all described health problems and bring them back to normal 
health 
Was disease labelled or named? Yes ± each patient had a different disease 
Did the study examine whether 
quality of life improving or life 
extending treatments are 
preferred for end of life 
patients? 
No 
What were respondents 
choosing between (or choosing 
to do)? 
Which of two patients to treat 
Was it possible to express 
indifference? 
No 
Were visual aids used? No 
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Record Stolk, E.A., Pickee, S.J., Ament, A.H. and Busschbach, J.J., 2005. 
Equity in health care prioritisation: an empirical inquiry into 
social value. Health Policy, 74(3), 343-355. 
Strength of preference 
examined at the individual 
respondent level? 
No 
Number of tasks completed by 
each respondent 
45 
Time taken to complete survey 
reported? 
Yes ± 20 minutes on average 
Summary of finding: end of life 
vs. non-end of life 
Evidence not consistent with an end of life premium 
Summary of finding: quality of 
life improvement vs. life 
extension 
Not examined / reported 
Other results of potential 
interest 
Fair innings and (to a lesser extent) proportional shortfall approaches to 
priority-setting were highly correlated with the observed rank order 
LPSOLHGE\UHVSRQGHQWV¶FKRLFHV 
Other factors examined Fair innings, severity, proportional shortfall 
Impact of background 
characteristics reported? 
Yes ± there were no major differences in the rank orderings of the three 
respondent subgroups  
Were qualitative data or 
explanatory factors sought? 
No / not reported 
Was any reference made to 
age-related preferences? 
Yes ± treatments for elderly patients were not valued as higher 
prospective health theories that ignore the past (i.e. age) would have 
predicted 
Was any reference made to 
time-related preferences? 
No 
 
 
